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Musculoskeletal symptoms (including arthralgias, myalgia, and muscle stiffness) are experienced 
by up to 85% of women undergoing aromatase inhibitor (AI) therapy for breast cancer, and are the 
number one contributor to the high treatment discontinuation rate. The purpose of this dissertation 
study was to examine the trajectories of musculoskeletal symptoms and related factors during the 
first 18 months of AI therapy for breast cancer. This is an ancillary study to a parent study, the 
Anastrozole Use in Menopausal Women (AIM). The AIM study provided data on pain, 
musculoskeletal symptoms, and candidate phenotypic factors for two cohorts of women (n=380) 
(cohort 1: women with early stage breast cancer who receive anastrozole; cohort 2: age- and 
education-matched women without cancer) at baseline (before initiation of AI therapy for breast 
cancer cohort), 6, 12, and 18 months after baseline. Based on the bio-banked DNA provided by a 
subgroup of participants (n=243), we genotyped 46 single nucleotide polymorphisms (SNPs) 
among the 25 candidate genes which were selected from a biological pathway analysis. Our results 
showed that a significant proportion of women experienced mild or moderate pain and 
musculoskeletal symptoms in a persistent or linearly increasing manner over the first 18 months 
of AI therapy. A profile of protective and risk factors across one or more phenotypes was 
identified. The protective phenotypic factors included older age, receipt of chemotherapy, older 
first menstrual period age, married/partnered, having an administrative level of occupation (vs 
unskilled/unemployed), having regular periods for most of one’s life, greater numbers of 
pregnancies, and having a history of tubal ligation. The phenotypic risk factors included receipt of 
 v 
AI therapy, greater anxiety, pain severity, depressive symptoms, fatigue at baseline, and having a 
history of arthritis, hysterectomy, or menopausal symptoms. A profile of protective and risk 
polymorphisms was identified. Variations in CYP19A1 (rs1008805) and NOS3 (rs1799983) were 
associated across phenotypes. The protective polymorphisms included BDNF rs6265, COMT 
rs4633 and rs887200, CXCL8 rs4073, ESR2 rs2772163, IL1B rs16944, RANKL rs1054016, VDR 
rs4516035 and rs731236. The risk polymorphisms included CYP19A1 rs1008805, CYP3A4 
rs35599367, COMT rs165774, NOS3 rs1799983, OPG rs2073618, OPRM1 rs1799971, and 
TCL1A rs7158782 and rs7159713. 
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1.0 PROPOSAL INTRODUCTION AND SPECIFIC AIMS 
Breast cancer is the most common cancer diagnosed in women in the United States. The 
National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline for Breast Cancer 
recommends that women with hormone receptor positive disease, who are postmenopausal at 
diagnosis, receive 5-10 years of endocrine therapy with an aromatase inhibitor (AI). While AI 
therapy clearly improves the overall and disease-free survival in postmenopausal women with 
breast cancer, this treatment is associated with multiple symptoms that may have a detrimental 
impact on medication adherence and quality of life. Musculoskeletal symptoms including 
arthralgias, myalgia, and muscle stiffness, are the most commonly reported symptoms, effecting 
3.6-89% of women receiving AI therapy. However, most clinical studies of musculoskeletal 
symptoms have only followed women with breast cancer through less than the first year of AI 
therapy; thus the trajectory of musculoskeletal symptoms after the first year is not known. In 
addition, little is known about the inter-individual variability of musculoskeletal symptoms and its 
associated phenotypic factors (demographic-, disease-, and individual-related characteristics) 
during AI therapy for breast cancer. 
Moreover, the mechanisms underlying musculoskeletal symptoms during AI therapy are 
not completely understood. In the past decade, the etiology of musculoskeletal symptoms during 
AI therapy has been explored from perspectives of estrogen deprivation, pharmacogenetics of AI 
metabolism, and vitamin D deficiency. The genotypic factors associated with the inter-individual 
variability in musculoskeletal symptoms during AI therapy need to be further explored and 
examined. In addition, since musculoskeletal symptoms are widely prevalent among post-
menopausal women due to menopausal status and comorbidities (e.g., osteoporosis, arthritis, 
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fibromyalgia etc.), there is a need to broaden the scope of investigation to explore the phenotypic 
and genotypic factors associated with potential mechanisms and to better understand the inter-
individual variability of musculoskeletal symptoms during AI therapy.  
The purpose of this dissertation study was to gain a greater understanding of trajectories of 
musculoskeletal symptoms associated with the first 18 months of anastrozole (the mostly used 
aromatase inhibitor) therapy among postmenopausal women with breast cancer. Phenotypic 
factors associated with the distinct trajectories were determined. The influence of genotypic factors 
on the distinct trajectories were explored.  
The specific aims of the dissertation study were to: 
Aim 1: Identify distinct latent classes of 18-month trajectories of musculoskeletal 
symptoms for two cohorts of postmenopausal women (cohort 1: women with early stage breast 
cancer who receive anastrozole; cohort 2: age- and education-matched women without cancer). 
Aim 2: Determine phenotypic factors (demographic-, disease-, and individual-related 
characteristics) associated with the membership for the distinct latent classes of trajectories for 
musculoskeletal symptoms. 
Aim 3: Explore the genotypic factors (DNA variation in genes related to estrogen 
biosynthesis and musculoskeletal pain) associated with the distinct latent classes of trajectories for 
musculoskeletal symptoms. 
This dissertation study was an ancillary study to the Anastrozole Use in Menopausal 
Women (AIM) study (R01CA107408, PI: Dr. Catherine Bender). The AIM study was a 
prospective cohort study with repeated assessments at pre- and 6, 12, and 18 months post initiation 
of adjuvant therapy. The primary purpose of the AIM study was to examine and compare the effect 
of anastrozole on cognitive function among four groups of postmenopausal women: women with 
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early stage breast cancer who receive chemotherapy plus anastrozole (ChemoAnast), anastrozole 
alone (AnastAlone), chemotherapy only (ChemoOnly), and women without breast cancer who 
were matched on age, and years of education to the breast cancer cohorts. Data on 
sociodemographic status and clinical characteristics related to participants’ breast cancer were 
collected at the baseline assessment. Assessments of pain, mood (depression and anxiety), fatigue, 
and other symptoms commonly experienced by women receiving endocrine therapy were 
performed at each time point. DNA samples were extracted from blood or saliva and banked for a 
subset of participants. 
The dissertation study focused on three of the AIM study cohorts: ChemoAnast, 
AnastAlone, and healthy control. Data on musculoskeletal symptoms from the Brief Pain 
Inventory and Breast Cancer Prevention Trial Symptom Checklist at baseline (before initiation of 
AI therapy for the breast cancer cohorts) and 6, 12, and 18 months post baseline were analyzed to 
investigate the trajectory patterns for pain and musculoskeletal symptoms. Baseline demographic-，
disease-, and individual characteristics, mood and fatigue were used to determine their associations 
with the membership for the distinct latent classes of trajectories for musculoskeletal symptoms. 
New genotype data of selected candidate genes were generated using the bio-banked DNA 
samples. The association between the DNA variation and the distinct latent classes of trajectories 
for musculoskeletal symptoms were explored. 
1.1 VARIABLE FRAMEWORK  
The framework of this dissertation study was adapted from the Symptom Experience 
Model (SEM), developed by Armstrong (Armstrong, 2003) and the NIH Symptom Science Model 
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(Cashion et al., 2015). In the SEM, symptom experience is a multi-dimensional concept defined 
as the “perception of the frequency, intensity, distress, and meaning of symptoms as they are 
produced and expressed” (Armstrong, 2003, P.602). Symptoms can be associated with 
demographic characteristics (e.g., age, gender, marital status, race, culture, role, education, and 
socioeconomic status), disease characteristics (e.g., type and state, type of treatment, and comorbid 
medical and clinical factors), and individual characteristics (e.g., health knowledge, values, past 
experience, etc.). The NIH Symptom Science Model is used to organize and guide biobehavioral 
symptom management. It starts with identifying a complex symptom, followed by phenotypic 
characterization, biomarker discovery, and clinical application (Cashion et al., 2015).  
In this dissertation study, the musculoskeletal symptom experience was conceptualized as 
the perception of the occurrence, intensity, distress, and location occurring as symptoms are 
produced and expressed. Musculoskeletal symptoms included joint pain (arthralgia), muscle pain 
(myalgia), and muscle stiffness. Phenotypic factors associated with musculoskeletal symptoms 
include demographic-, disease-, individual-related characteristics adapted from the SEM. 
Genotypic factors (DNA variance in candidate genes) associated with musculoskeletal symptoms 
were added by adapting from the NIH Symptom Science Model and were explored as the basis for 
better understanding the inter-individual variability of musculoskeletal symptoms (Figure 1).  
1.2 INNOVATION 
This dissertation study is innovative in a number of ways. 
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• This study is a pioneering work because it is the first study to examine the inter-
individual variability of musculoskeletal symptoms during AI therapy for breast cancer 
by identifying distinct latent classes (i.e., subgroup) of trajectories. 
• This study is one of the first clinical studies to extend the description of pain and 
musculoskeletal symptoms through 18 months of AI therapy for breast cancer. 
• This study explores genotypic factors associated with trajectory patterns for 
musculoskeletal symptoms, which has potential to expand the understanding of the 
mechanisms underlying musculoskeletal symptoms during AI therapy. 
1.3 BACKGROUND AND SIGNIFICANCE 
Breast cancer is the most commonly diagnosed cancer and the second leading cancer 
mortality among women worldwide (Torre et al., 2012). It is estimated that there will be 252,710 
new breast cancer diagnoses and 40,610 deaths in 2017 in the United States (Siegel, Miller, & 
Jemal, 2017). Approximately 80% of post-menopausal women with breast cancer have hormone 
receptor (estrogen and/or progesterone receptor) positive disease (Osborne CK, 1998), with 
circulating estrogen levels influencing tumor growth and recurrence. With the application of third-
generation aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, the 
disease-free and overall survival rates have been significantly improved for post-menopausal 
women with breast cancer (Goss et al., 2016; Romera et al., 2011). In 1995, oral anastrozole, at a 
dose of one milligram daily, was initially approved by the United States Federal Drug 
Administration (FDA) (Drugs@FDA, 1995) for adjuvant therapy in postmenopausal women with 
early stage, hormone receptor-positive breast cancer and as first-line treatment of postmenopausal 
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women with hormone receptor-positive or hormone receptor unknown locally advanced or 
metastatic breast cancer. The National Comprehensive Cancer Network (NCCN) Clinical Practice 
Guideline for Breast Cancer recommends that women with hormone receptor positive disease, who 
are postmenopausal at diagnosis, receive at least 5 years of endocrine therapy with an aromatase 
inhibitor (AI) (NCCN, 2017). Furthermore, evidence shows that extension of adjuvant AI therapy 
to 10 years significantly improves disease-free survival and lowered contralateral breast cancer 
incidence (Goss et al., 2016). Therefore, 5-10 years of AI therapy is a vital component of 
systematic adjuvant treatment for postmenopausal women with hormone receptor positive breast 
cancer. 
Musculoskeletal-related adverse events and symptoms were reported in early clinical trials 
of AI drugs. In the randomized phase III trials of AI, the incidence of musculoskeletal adverse 
events (e.g., fracture, osteoporosis, and osteopenia) and symptoms (e.g., arthralgias, myalgia, 
stiffness, etc.) were significantly higher compared to women who received the selective estrogen 
receptor modifier (SERM), tamoxifen or placebo. The occurrences of osteoporosis in the AI groups 
were 7.3% -11.0% and of fractures were 0.8% - 5.3% (Arimidex, 2006, 2008; Jakesz et al., 2005, 
2007; Coates et al., 2007; Coombes et al., 2007; Goss et al., 2005). When extending AI adjuvant 
therapy to 10 years in the MA.17R trial, women who received 10 years of AI showed greater 
numbers of bone fractures and new-onset osteoporosis compared to women who received 5 years 
of AI plus 5 years of placebo (Goss et al., 2016). In terms of musculoskeletal symptoms, the 
occurrence of arthralgias, myalgia, and bone pain were reported 1% - 35.6%, 7.1% - 15%, and 5% 
- 19%, respectively (Arimidex, 2006; Boccardo et al., 2006; Coates et al., 2007; Coombes et al., 
2007; Howell et al., 2005; Jakesz et al., 2005, 2007).  
 7 
However, with wider clinical use of AI therapy, accumulating evidence suggests that 
symptoms associated with endocrine therapy were underestimated in the clinical trials perhaps due 
to the focus on efficacy and safety. Ruhstaller et al. reported that hot flashes/sweats (70% vs 38-
40 in clinical trials), low energy (45% vs 9-15% in clinical trials), fluid retention (22% vs 7% in 
clinical trials), and vaginal dryness (30% vs. 3% in clinical trials) were significantly underrated in 
clinical trials of endocrine therapy (Ruhstaller et al., 2009). Moreover, the symptoms associated 
with AI treatment may have a detrimental impact on women’s ability to adhere to therapy, as well 
as their functional status and quality of life (Aiello Bowles et al., 2012; Kidwell et al., 2014; 
Olufade, Gallicchio, MacDonald, & Helzlsouer, 2015). Significantly, 5% - 10% of AI users in 
clinical trials and 25% in clinical settings prematurely discontinued treatment due to 
musculoskeletal symptoms (Henry et al., 2012). Between 13% and 50% of the discontinuation of 
AI therapy is due to AI associated arthralgias (Crew et al., 2007; Dizdar et al., 2009; Henry et al., 
2008). Therefore, it is important to gain a better understanding of these musculoskeletal symptoms 
during AI therapy in clinical settings.  
1.3.1 Phenotype and phenotypic factors associated with musculoskeletal symptoms during 
AI therapy 
A literature review on the occurrence, intensity, and distress of musculoskeletal symptoms 
during AI therapy among women with breast cancer was conducted. Studies published through 
February 2017 were searched using combination of key terms (Table 1) in MEDLINE®, PubMed, 
and CINAHL®.  
Musculoskeletal symptoms have been shown to be a cluster of highly prevalent symptoms 
with moderate to severe intensity associated with aromatase inhibitor therapy for breast cancer. 
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Thirty-one studies reported musculoskeletal symptoms, including arthralgias (pain in joints), 
myalgia (pain in muscle), and muscle stiffness (Table 2) (Aiello Bowles et al., 2012; Boonstra et 
al., 2013; Brown et al., 2014; Chim et al., 2013; Crew et al., 2007; Dizdar et al., 2009; Egawa et 
al., 2016; Gallicchio et al., 2012; Garreau et al., 2006; Hadji et al., 2014; Horimoto et al., 2009; 
Hu et al., 2016; Kyvernitakis et al., 2014; Laroche et al., 2014; Lintermans et al., 2014; Lu et al., 
2011; Mao et al., 2009, 2011; Napoli et al., 2010; Oberguggenberger et al., 2011; Ohsako et al, 
2006; Olufade et al., 2015; Presant et al., 2007; Sagara et al., 2010; Servitja et al., 2012; Shi et al., 
2013; Singer et al., 2012; Swenson et al., 2013; Waltman et al., 2009; Wang et al., 2013). The 
occurrence of musculoskeletal symptoms ranged widely from 3.6% to 89%; arthralgias and 
myalgia were the most prevalent symptoms with occurrences ranging from 3.6% to 89%. Between 
25% and 72% of AI users reported joint/muscle stiffness (Table 3). Menas et al. and Mao et al. 
reported that 32% to 82% of arthralgias began in the first 6 months after initiation of AI treatment. 
An average of 8 joints were affected with arthralgias; the hands, knees, and wrists were the most 
common joints involved. Other joints that were reported to be affected included the shoulder, 
spine, fingers, elbows, and feet. Thirty-three percent of AI users experienced arthralgias all day 
(Mao et al., 2009; Menas et al., 2012). For those who experienced arthralgias and myalgia, 31.5%-
46% reported moderate to severe intensity (Chim et al., 2013; Crew et al., 2007; Mao et al., 2009; 
Presant et al., 2007). The average intensity of arthralgias was moderate to severe and ranged from 
4.9 to 7.5 out of 10 (as extreme severity) (Boonstra et al., 2013; Shi et al., 2013; Servitja et al., 
2012; Present et al., 2007). The onset severity of arthralgia was 5.23 on a 10-point scale (Shi et al., 
2013). Swenson et al. reported a trend toward increasing intensity of musculoskeletal symptoms 
during the first 6 months after initiation of AI treatment (Swenson et al., 2013). In terms of distress 
of musculoskeletal symptoms, 48% - 64.3% of AI users reported disturbances with daily activities 
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(Table 3) (Egawa et al., 2016; Waltman et al., 2009). However, the phenotype of musculoskeletal 
symptoms during AI therapy is not fully understood. Firstly, although the occurrence and severity 
of musculoskeletal symptoms are well-documented, there is a lack of research on the degree of 
distress and meaning associated with musculoskeletal symptoms. According to the Symptom 
Experience Model (Armstrong, 2003), symptom experience is a multi-dimensional concept with 
four domains: frequency (occurrence is a dichotomous concept of frequency), intensity (or 
severity), distress (or interference), and meaning. To date, only four studies (Egawa et al., 2016; 
Shi et al., 2013; Swenson et al., 2013; Waltman et al., 2009) investigated the distress associated 
with musculoskeletal symptoms; none of the studies examined the meaning of musculoskeletal 
symptoms S. However, the domains of distress and meaning of musculoskeletal symptoms may 
significantly influence adherence to therapy, treatment outcomes (e.g., quality of life) of breast 
cancer survivors and their ability to cope with musculoskeletal symptoms during AI therapy.  
Furthermore, the trajectory of musculoskeletal symptoms during the course of AI therapy 
is not fully described. To date, most of the studies focusing on musculoskeletal symptoms adopted 
a cross-sectional design. And the follow-up period of the few longitudinal studies completed to 
date was no more than 12 months (from pre-therapy). Thus, there is a need to extend follow-up 
period beyond the first year of therapy to better describe the trajectories of musculoskeletal 
symptoms. 
In addition, it is not clear whether there are subgroups of women who experience more 
severe musculoskeletal symptoms or who experience greater distress. Among breast cancer 
survivors, inter-individual variability in the experience of several common symptoms during 
surgery and adjuvant therapies have been reported, including the trajectories of fear of recurrence 
(Dunn et al., 2015), depressive symptoms after surgery (Dunn et al., 2011), pain after 
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chemotherapy (Langford et al., 2016), weight changes during chemotherapy (Liu et al., 2014), 
anxiety pre- and post-surgery (Kyranou et al., 2014), and fatigue during and after radiation therapy 
(Dhruva et al., 2010). The wide range of musculoskeletal symptoms prevalence (3.6% - 89%) 
suggests that there could be variability in the experience of these symptoms as well. However, no 
studies to date have examined variability in musculoskeletal symptoms during AI therapy to 
determine whether there are subgroups of women who are vulnerable to greater severity or distress 
of musculoskeletal symptoms. 
The phenotypic factors associated with musculoskeletal symptoms during AI therapy are 
summarized in Table 4. Women with longer menopause duration, more severe breast symptoms, 
more joint-related comorbidity, presence of pain at pre-therapy, and vitamin D insufficiency were 
more likely to experience arthralgias (Castel et al., 2013; Crew et al.,2007; Laroche et al., 2014; 
Mao et al., 2011a; Shi et al., 2013; Waltman et al., 2009; Wang et al., 2013b). However, whether 
BMI, age and prior chemotherapy predicted arthralgias is not clear due to conflicting evidence 
(Castel et al., 2013; Crew et al., 2007; Mao et al., 2011a; Menas et al., 2012; Shi et al., 2013; Wang 
et al., 2013). The basis for some of this inconsistency may be due to methodological limitations 
(e.g., small samples, cross-sectional designs, heterogeneous measurement instrumentations, etc.) 
and diverse analytic methods used across studies (e.g., mean comparison, logistic regression, 
ANOVA, etc.) Additional longitudinal study is needed to confirm the phenotypic characteristics 
that are associated with musculoskeletal symptoms during AI therapy for breast cancer. 
1.3.2 Hypothesized molecular basics of musculoskeletal symptoms during AI therapy 
In the era of precision medicine, with the need for personalized symptom prediction and 
management, it is of utmost importance to explore the mechanisms underlying symptoms. 
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However, the underlying mechanism of musculoskeletal symptoms during AI therapy is largely 
unknown (Borrie & Kim, 2017). The molecular basis of musculoskeletal symptoms during AI 
therapy was hypothesized mainly from the perspectives of estrogen deprivation. Vitamin D 
deficiency, and pharmacogenetics of AI metabolism were also studied to uncover the inter-patient 
variability of musculoskeletal symptoms during AI therapy. Moreover, since musculoskeletal 
symptoms are widely experienced among post-menopausal women (hormone decline) and 
comorbidities (e.g., osteoporosis, arthritis, and fibromyalgia), there is a need to broaden the scope 
to explore the genetic factors associated with comorbidity-related musculoskeletal symptoms to 
better understand the individual variance in musculoskeletal symptoms during AI therapy. 
1.3.2.1 Mechanism of action of the aromatase inhibitors 
Estrone and estradiol are two major types of estrogen present in postmenopausal women. 
Aromatase is an enzyme transcribed from the CYP19A1 gene that catalyzes estrogen biosynthesis 
through the conversion of testosterone to estradiol and androstenedione to estrone. In pre-
menopausal women, estrogen is produced in the ovaries and adipose tissue. Among post-
menopausal women, adipose tissue is the major source of estrogen synthesis (Simpson, 2003). 
Aromatase is expressed across multiple human tissues including the ovaries, testes, adipose tissue, 
brain, muscle, skin fibroblasts, and osteoblasts of bone (Czajka-Oraniec & Simpson, 2010). AIs 
block the activity of aromatase by reversibly binding (for letrozole and anastrozole) or irreversibly 
binding (for exemestane) to the enzyme. Letrozole and anastrozole bind to the AI substrate-binding 
site and prevent binding of androgens, thus limiting the catalytic conversion of androgens to 
estrogen. Exemestane binds irreversibly to the AI active site to inactivate the enzyme in a process 
commonly referred to as ‘suicide inhibition’ (Chumsri et al., 2011). Letrozole (2.5mg/day), 
anastrozole (1mg/day), and exemestane (25mg/day) inhibit estrogen biosynthesis by the rates of 
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99%, 97%, and 98%, respectively (Fabian, 2007). Use of AIs reduce estrogen synthesis and lower 
the circulating estrogens below the detectable level of most clinical assays (Geisler et al., 2002), 
and thereby reducing estrogen-dependent cellular proliferation (Campos, 2004). 
1.3.2.2 Estrogen deprivation 
Since 1925, estrogen decline has been reported to link to arthralgias among women without 
cancer (Cecil & Archer, 1925). Ho et al. reported that sudden estrogen decline can trigger 
arthralgias (Ho et al., 1999). The occurrence of increased joint pain and stiffness in peri-
menopausal women (41%) was significantly higher than the occurrences among pre- and post-
menopausal women (25% and 29%, respectively). Moreover, results from Women’s Health 
Initiative (WHI) showed that hormonal replacement therapy (HRT) alleviated arthralgia and 
improved joint health among postmenopausal women (Cirillo et al., 2006). In addition, lower 
levels of estrogen were reported to be associated with arthralgias among women with breast cancer 
receiving AI therapy. Wang et al. found that women with breast cancer suffering from AI-related 
arthralgias had significantly lower levels of estradiol compared to those without arthralgias (Wang 
et al., 2015). With the accumulating evidence suggesting that arthralgias are associated with 
estrogen decline and lower levels of circulating estrogen, estrogen deprivation is the main 
hypothesis of the molecular basis of musculoskeletal symptoms during AI therapy.  
However, there are conflicting results regarding the polymorphism of genes related in 
estrogen biosynthesis for musculoskeletal symptoms during AI therapy among women with breast 
cancer. For example, Park et al. reported a strong association between arthralgias and haplotype 
M_3_5 within CYP19A1, which contains 14 SNPs (Park et al., 2011). Lintermans et al. and Garcia-
Giralt et al. failed to replicate this association with several SNPs from the M_3_5 haplotype 
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(Garcia-Giralt et al., 2013; Lintermans et al., 2016). More studies are needed to confirm the 
robustness of the identified associations. 
1.3.2.3 Variation of AI metabolism 
In clinical practice, switching from one AI to another is one of the methods used to manage 
intolerant musculoskeletal symptoms (e.g., discontinuation of AI therapy due to severe 
arthralgias), since research has showed that 71.5% of patients may continue AI therapy by 
switching from anastrozole to letrozole (Briot et al., 2010). Moreover, although the dosage of AIs 
is fixed (2.5mg/day for Letrozole, 1mg/day for anastrozole, and 25mg/day for exemestane), the 
drug plasma concentration of AIs has 10-12 fold’ variation (Desta et al., 2011; Lazarus et al., 2010; 
Jeong et al., 2009; Kamdem et al, 2010, 2011). Therefore, variation in AI metabolism was 
hypothesized to be potentially associated with individual variability of musculoskeletal symptoms 
during AI therapy (Borrie & Kim, 2017; Gervasini et al., 2017). Genotype of five genes (CYP2A6, 
CPY3A4, CYP3A5, CBCA1 and UGT2B17) has been reported to be potentially associated with 
plasma concentration or metabolism of AIs. (Desta et al., 2011; Wang, et al, 2016; Lamba et al., 
2012; Sun, et al., 2010; Gervasini et al., 2017).  
1.3.2.4 Vitamin D deficiency 
Vitamin D deficiency has been linked to chronic pain. Increasing evidence suggests that 
pain pathways associated with cortical, immunological, hormonal, and neuronal changes are 
potentially influenced by Vitamin D levels (Shipton & Shipton, 2015). Furthermore, vitamin D 
deficiency has been associated with the occurrence and intensity of musculoskeletal symptoms 
during AI therapy. AI users who developed musculoskeletal symptoms were more likely to have 
vitamin D deficiency at pre-therapy (Singer et al. 2014; Waltman et al. 2009). Servitja et al 
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reported that lower vitamin D levels were significantly associated with worse intensity of 
musculoskeletal symptoms during AI therapy (Servitja et al., 2015). In addition, a phase II 
randomized controlled trial showed that daily supplementation with high dose vitamin D2 (50,000 
IU) for 8-16 weeks significantly alleviated pain severity and interference for women with breast 
cancer who developed musculoskeletal symptoms during AI therapy (Rastelli et al., 2011). 
However, the effect of vitamin D supplementation on musculoskeletal symptoms during AI 
therapy was not confirmed by another randomized controlled trial of 4,000IU vitamin D3 
supplement (Shapiro et al., 2016). Niravath et al reported that polymorphisms of the VDR (vitamin 
D receptor) may be associated with the occurrence of aromatase inhibitor associated arthralgias 
(Niravath et al., 2017). 
1.4 PRELIMINARY STUDIES 
1.4.1 Preliminary Study #1: A scoping review on symptoms with endocrine therapy for 
breast cancer 
The purpose of this scoping review was to map the symptoms during endocrine therapy 
for breast cancer to provide implications for current practice and suggestions for future research. 
PubMed, CINAHL®, and China Science Periodical Databases (CSPD) were searched to identify 
related studies published in English and Chinese language. Of the 2,551 articles identified, 57 
articles met inclusion criteria and were included in this scoping review (Zhu et al., 2019; Appendix 
C).  
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Main Results and Conclusions: Evidence for the 16 most studied symptoms and 15 most 
prevalent symptoms were synthesized. Five key symptoms associated with endocrine therapy were 
identified, including joint/muscle pain, hot flashes, low sexual interest/desire, joint/muscle 
stiffness, and fatigue/lack of energy. Future studies should focus on the domains of symptom 
intensity and distress, specific understudied symptoms, symptom clusters, and development of 
symptom assessment instruments specific to symptoms associated with endocrine therapy. 
1.4.2 Preliminary study #2: A literature review with biological pathway analysis on genes 
associated with musculoskeletal pain (MSKP) during treatment with aromatase 
inhibitors for breast cancer 
The goals of this literature review with biological pathway analysis were to 1) gain 
understanding of the genetic variation and biological mechanisms underlying MSKP with AI 
therapy, and 2) identify plausible biological pathways and candidate genes for future investigation. 
Genes associated with MSKP during AI therapy or genes involved in drug metabolism and drug 
response of AIs were identified from literature. Studies published through February 2019 were 
queried in PubMed®. The genes identified from the literature were entered into the QIAGEN’s 
Ingenuity® Pathway Analysis (IPA) software to generate canonical pathways, upstream 
regulators, and networks through a core analysis (Zhu et al., 2019; Appendix D). 
Main Results and Conclusions: Multiple genes and molecular-level etiologies may 
contribute to MSKP with AI therapy in women with breast cancer. Seventeen genes were 
identified, including ABCB1, ABCG1, CYP17A1, CYP19A1, CYP27B1, CYP2A6, CYP3A4, 
CYP3A5, ESR1, OATP1B1, OPG, RANKL, SLCO3A1, TCL1A, UGT2A1, UGT2B17, and VDR. 
These genes are involved in encoding bone remodeling regulators, drug metabolizing enzymes 
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(cytochrome P450 family, UGT family) or drug transporters (ABC transporters, OAT 
transporters). Multiple plausible biological pathways (e.g., nicotine degradation, melatonin 
degradation) and candidate genes (e.g., NFKB, HSP90, AKT, ERK1/2, FOXA2) were proposed for 
future investigation based on the IPA results. 
 
1.5 DESIGN AND METHODOLOGY 
1.5.1 Study design 
This dissertation study was an ancillary study to the Anastrozole Use in Menopausal 
Women (AIM) study (R01CA107408, PI: Dr. Catherine Bender). The AIM study was a 
prospective cohort study with repeated assessments at pre- and 6, 12, and 18 months post initiation 
of adjuvant therapy. The primary aim of the AIM study was to examine and compare the effect of 
anastrozole on cognitive function among four groups of postmenopausal women: women with 
early stage breast cancer who receive chemotherapy plus anastrozole (ChemoAnast), anastrozole  
alone (AnastAlone), chemotherapy only (ChemoOnly), and  women without breast cancer who 
were matched on age, and years of education to the breast cancer cohorts. Data on 
sociodemographic status and clinical characteristics related to participants’ breast cancer were 
collected at the baseline assessment. Assessments of pain, mood (depression and anxiety), fatigue, 
and symptoms commonly experienced by women receiving endocrine therapy were performed at 
each time point. DNA samples were extracted from blood or saliva and banked for a subset of 
participants. 
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The dissertation study focused on three of the AIM study cohorts: ChemoAnast and 
AnastAlone, and women without cancer. Data on pain and musculoskeletal symptoms from the 
Brief Pain Inventory (Cleeland & Ryan, 1994) and Breast Cancer Prevention Trial Symptom 
Checklist (Stanton, Bernaards & Ganz, 2005) at baseline (before initiation of AI therapy for the 
breast cancer cohorts) and 6, 12, and 18 months post baseline were analyzed to investigate the 
trajectory patterns of musculoskeletal symptoms. Baseline phenotypic factors including 
demographic-, disease-, and individual characteristics were used for to examine the relationship 
between these factors and group membership of trajectories for musculoskeletal symptoms. New 
genotype data of selected candidate genes were generated using the banked DNA samples. The 
association between the DNA variation and the distinct latent classes of trajectories for 
musculoskeletal symptoms were explored. 
 
1.5.2 Setting and sample 
The participants were recruited from the Comprehensive Breast Care Program of the 
University of Pittsburgh Cancer Institute (UPCI), which was comprised of Magee Women’s 
Hospital, Hillman Cancer Center, and Shadyside Hospital. Inclusion criteria for ChemoAnast and 
AnastOnly cohorts were: 1) female; 2) diagnosed with stage I, II, and IIIa breast cancer based on 
the Tumor, Node, Metastasis Classification System and confirmed by oncologist; 3) eligible to 
receive either chemotherapy + anastrozole, or anastrozole alone; 4) postmenopausal defined as 
amenorrhea persisting for an entire year, oophorectomy, or hysterectomy and age greater than 51 
years; 5) maximum age of 75 years; 6) able to speak and read English; and 7) completed a 
minimum of 8 years of education. Exclusion criteria for all subjects were: 1) self-report of 
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hospitalization for psychiatric illness within the last 2 years; 2) a prior diagnosis of neurologic 
illness; 3) clinical evidence of distant metastases including the central nervous system, or 4) prior 
diagnosis of cancer.  
The AIM study was approved by the University of Pittsburgh IRB, and all participants 
provided written informed consent. A subgroup of participants in the AIM study agreed to 
provide a blood or saliva sample. The DNA of these sample were extracted and bio-banked in a 
comprehensive Nursing and Basic Science Laboratory. 
1.5.3 Measures and procedure 
The baseline characteristics (demographic-, disease-, and individual-related 
characteristics) were recorded at the initial study time point. Depression, anxiety, and fatigue 
before adjuvant therapy were assessed by Beck Depression Inventory (second edition) (Groth-
Marnat, 1990), Profile of Mood States Tension/Anxiety and Fatigue/Inertia subscale (Terry et al., 
1999) respectively. Data on pain and musculoskeletal symptoms from the Brief Pain Inventory 
(Cleeland & Ryan, 1994) and Breast Cancer Prevention Trial Symptom Checklist (Stanton et al., 
2005) were collected at pre- and 6, 12, and 18 months post initiation of adjuvant therapy. 
The Brief Pain Inventory (BPI) short form was used to assess self-report of severity of pain 
and the impact of pain on daily functions, location of pain, and pain medications in the past week. 
The severity of pain (worst, least, average, and right now) was assessed by 4 items with a scale 
ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Pain interference with general 
activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of 
life are assessed by 7 items with a scale ranging from 0 (does not interfere) to 10 (completely 
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interferes). Cronbach’s alpha reliability of BPI has been reported ranging from 0.77 to 0.91 
(Cleeland & Ryan, 1994). 
The musculoskeletal symptoms were assessed by the musculoskeletal component of the 
Breast Cancer Prevention Trial (BCPT) Symptom Checklist that include 5 items (general aches 
and pains, joint pains, muscle stiffness, swelling of hands or feet, and numbness or tingling). 
Participants were asked to indicate the presence or absence of each musculoskeletal symptom and 
rate its associated distress on a five-point Likert scale ranging from 0 (not at all) to 4 (extremely). 
Prior studies have demonstrated good reliability and validity with internal consistency reliability 
exceeding 0.70. The Cronbach’s alpha for all items was reported as 0.81 (Stanton et al., 2005; 
Cella et al., 2008; Terhorst et al., 2011). 
1.5.4 Selection of candidate genes and SNPs, and genotyping 
A comprehensive, 3-step literature review with broadened scope was conducted to identify 
genes associated with musculoskeletal symptoms in 1) breast cancer, 2) cancer, and 3) a population 
without cancer (e.g., low back pain, fibromyalgia, arthritis-related pain, knee pain, widespread 
musculoskeletal pain etc.). Studies published through June 2017 were queried using combinations 
of key terms in PubMed. From the literature review, 13 genes were identified related to 
musculoskeletal symptoms with AI therapy for breast cancer, including ESR1, CYP17A1, 
CYP19A1, CYP27B1, CYP2A6, CYP3A4, CYP3A5, IGF1, TCL1A, OPG, RANKL, UGT2B17, and 
VDR. When broadening the review scope to include musculoskeletal symptoms in populations 
with/without cancer, the number of identified genes increased to 72. 
The 72 genes identified from the literature review were entered into a gene-gene pathway 
analysis sing QIAGEN’s Ingenuity® Pathway Analysis (IPA) software, and 23 genes were 
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selected based upon the current evidence of their association with musculoskeletal symptoms with 
AI therapy and the numbers of direct and indirect interactions (including binding, inhibiting, acting 
on, inhibiting and acting on, leading to, and translocating to) with other candidate genes in the 
IPA. The 23 candidate genes are BDNF, CCL2, CXCL8, CYP17A1, CYP19A1, CYP27B1, 
CYP2A6, CYP3A4, CYP3A5, ESR1, ESR2, IGF1, IL1A, IL1B, IL1RN, LIF, MMP13, NOS3, 
TCL1A, OPG (TNFRSF11B), RANKL (TNFSF11), VDR, and WNT5A. Three additional genes 
(COMT, IL-6, and OPRM1) that have been published to be closely associated with chronic pain 
were added to the candidate gene list (Knisely et al., 2019). A total of 26 candidate genes were 
initially selected. Tagging SNPs and literature-driven functional SNPs for these 26 candidate genes 
were selected for investigation. Tagging SNPs were selected using the Phase III HapMap database. 
Tagging SNPs were required to be common (minor allele frequency of ≥ 0.05) in public databases. 
The selection and prioritization of candidate genes, and the process of the ingenuity pathway 
analysis have been previously reported (Zhu et al., 2019, Appendix D). 
Of the 283 participants who provided a blood or saliva sample from the AIM study, 243 
who had complete phenotype and phenotypic factor profile were genotyped and included in the 
genetic analysis. Extracted DNA samples were genotyped with the Sequenom iPLEX 
MassARRAY platform or ABI TaqMan allelic discrimination. To ensure robust genetic 
association analyses, SNPs with call rates of <90%, minor allele frequency of >0.05, or Hardy-
Weinberg estimates with p<0.05 were excluded. Table 5 lists the 46 SNPs among the 25 candidate 
genes that met all the quality control criteria and were included in the genetic analyses. (CYP3A5 
was removed from the candidate gene list because neither the tagging SNP nor functional SNP 
was identified). 
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1.6 DATA ANALYSIS 
1.6.1 Descriptive statistics 
Variables were described by descriptive statistics. For nominal variables, frequency, 
percentage, range, and mode will be counted and computed. For ordinal variables, frequency, 
percentage, mode, median, interquartile range, semi-interquartile range, and range were counted 
and computed. For ratio variables, mean, standard deviation, range were computed. If the 
distribution of ratio variables was very skewed, then non-parametric statistics (e.g., median, 
interquartile range, and semi-interquartile range) were further computed to better describe the 
skewed variables. Bar chart and pie chart were used to describe nominal and ordinal variables 
graphically. Histogram and box plot were used for ratio variables. Distribution of variables were 
described by cross-tabulation contingency table (nominal and ordinal variables), histogram, and 
scatterplots. 
1.6.2 Data screening procedures 
The data screening procedure were started with data accuracy screening through generating 
descriptive statistics and graphical plots for each variable. For descriptive statistics, whether 
minimum and maximum values are in a reasonable range and whether mean or median are 
plausible were checked. The out-of-range values were checked whether there are data entry error 
or the values are messed with missing value code. The consistency of similar variables among 
different measures were checked, for example, whether the pain occurrence was consistent 
between the BPI and BCPT instruments. In terms of graphical plots, scatterplot and histogram 
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were generated for continuous and categorical variables respectively. For genotype data, Hardy-
Weinberg Equilibrium were checked to detect potential genotyping errors. 
Data were further screened to check the outliers, missingness, satisfaction with underlying 
assumptions, and need of data transformation.  
1.6.2.1 Outlier assessment 
Univariate and multivariate outliers were assessed. For categorical variables, uneven 
category splits were identified using frequency distributions and contingency table. Histograms 
and boxplots were used to identify cases removed from the distribution. Z-scores were calculated 
and case with extreme values (absolute value > 3.29) were considered as potential outliers. The 
presence of multivariate outliers was assessed using bivariate scatterplots and Mahalanobis 
distances.  
Outliers and influential values were also evaluated for regression model fitting. Outliers in 
Y were assessed using Jackknifed (deleted studentized) residuals, and outliers in X were assessed 
using leverage statistics. Boxplots of residual/leverage value and leverage plots of residual were 
generated to detect potential outliers. To explore influential values, the influence of the i-th 
observation on predicted values (DFFITS) and individual regression coefficients (DFBETAS) 
were calculated. To determine if the i-th observation exerts undue influence on a set of coefficients, 
Cook’s distance were calculated. Additionally, covariance ratio (COVARATIO) were computed 
to determine if the i-th observation improves or worsens the estimation ability of the model. 
1.6.2.2 Treatment of missing data 
Missing values for all variables at each time point were quickly screened by frequencies 
and percentages. Whether the missing pattern is missing completely at random was examined by 
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the Little’s MCAR test. If only a few cases (<5%) have missing data and appear to be at a random 
subset of the entire sample, simple deletion of missing cases was used to handle missingness. 
Alternatively, if data are missing from a considerable amount of cases or the pattern is not missing 
at random, appropriate strategies (e.g., multiple imputation, regression or expectation-
maximization algorithm, etc.) were used to address the missing data based on its missing pattern.  
1.6.2.3 Checking underlying assumptions 
The Group-based Trajectory modeling assumes that repeated observations on the same 
individual are independent conditional on trajectory group, meaning that the within-person 
correlation structure is explained completed by the estimated trajectory curve for each person’s 
group. Hence, this assumption of conditional independence for group-based trajectory modeling 
(GBTM) was examined. 
For the multivariate multinomial logistic regression model, the assumptions of 
independent, linear relationship between the logit of the independent variables and dependent 
variable, multicollinearity, additivity of effects of the independent variables (predictors), and 
proportional odds assumption were examined.  
1.6.3 Data analysis procedures 
The analysis plans for each specific aim are demonstrated below. 
Aim 1: Participants who 1) had completed more than two timepoint assessments with the 
BPI and BCPT, and 2) had complete profile of candidate risk factors, were included in the final 
analysis. Group-based trajectory modeling (GBTM) (Jones & Nagin, 2007; Nagin & Odgers, 
2010) was performed using SAS (version 9.4, SAS Institute, Inc., Cry, NC) to identify distinct 
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latent classes of trajectories for pain experience over the first 18 months of adjuvant AI therapy 
and the corresponding time period for the control cohort. Using GBTM, the BPI pain severity 
(average), BPI pain at worst, BPI pain interference (average), subscale of BCPT musculoskeletal 
symptoms (average), BCPT joint pain, BCPT muscle stiffness were modeled as a function of 
time under a censored normal model to identify distinct latent classes of trajectories, separately. 
The usage of analgesics was modeled as function of time under a logit model to identify distinct 
latent classes of trajectory. The number of distinct latent classes of trajectories was determined 
by the Bayesian Information Criteria (BIC), where the best-fitting model has the greatest BIC 
when comparing model BIC using the Bayes factor (Nylund, Asparouhov & Muthen, 2007). The 
shape of each estimated representative average trajectory for each class was determined by 
fitting regression model as polynomials of time (constant [intercept only], linear, quadratic, and 
cubic) and testing whether regression coefficients differ from zero (significance testing with t-
statistics). 
Aim 2: Multivariate multinomial logistic regression was conducted to determine the 
associated phenotypic factors (demographic and clinical characteristics) of trajectory group 
membership. All factors are time invariant. Using predicted trajectory group membership as a 
categorical variable, all factors of interest were screened one at a time using analysis of variance 
(ANOVA) for continuous variables (or Kruskal-Wallis H test if homogeneity of variances was 
violated), and Chi-square test (or Fisher exact test if sparse cells are encountered) for categorical 
variables. Variables that were not significant at the 0.30 level in the univariate analysis were not 
included in the multivariate multinomial logistic regression. A backward stepwise approach was 
used to create a parsimonious model. Statistical tests were 2-sided, and only predictors with p < 
0.05 were retained in the final model. 
 25 
Aim 3: Allele and genotype frequencies were determined by gene counting. Hardy-
Weinberg equilibrium was examined by the Chi-square test. Additive, dominant, and recessive 
genetic models were performed to assess the univariate association between each SNP and each 
trajectory group membership (phenotype) by Chi-square test (or Fisher exact test if sparse cells 
are encountered), individually. The genetic model that best fit the data, by maximizing the 
significance of the p-value, was selected for each SNP. Multinomial logistic regression analysis, 
which controlled for significant phenotypic factors (demographic and clinical characteristics) was 
conducted to examine the association between genotype of significant SNPs (selected from 
univariate analysis) and corresponding trajectory group membership (phenotype). A Backward 
stepwise approach was used to build a parsimonious model. Only predictors with p < 0.05 were 
retained in the final parsimonious model. Interactions between significant SNPs identified from 
multinomial logistic regression were further analyzed to explore the collective effects of 
significant SNPs.  
1.7 SAMPLE SIZE JUSTIFICATION 
The sample size of the parent study (AIM study) is fixed. Hence instead of determining 
sample size needs, we reported on the smallest effect sizes that would be detectable at a desired 
power of 0.80 at a level of significant of 0.05 for two-sided hypothesis testing given a fixed sample 
size of 380. 
According to the literature reporting on trajectories of other symptoms (e.g., anxiety, pain), 
2, 3 or 4 distinct classes of symptom trajectories were identified and with the 4 time points to be 
used in the proposed study up to a cubic polynomial trajectory shape may be estimated. For specific 
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aim 1 a cubic trajectory may be estimated with a minimum trajectory group size of 70 (20%) with 
at least 0.80 power. 
For the specific aim 2 examining the associations between candidate time-invariant 
phenotypic factors and predicted trajectory group membership, minimum effect sizes were 
determined that would be detectable with 0.80 power when testing hypotheses at a significance 
level of 0.05 for two-sided hypothesis testing. For time-invariant categorical variables (mostly 
binary predictors), contingency tables and Chi-squared test statistics for independence will be used 
to examine associations. For binary categorical predictor variables (e.g., chemotherapy, hormonal 
replacement therapy use, etc.) with a sample size of 380, we can detect effect sizes (w) as small as 
0.149, 0.165, and 0.176 for 2, 3, and 4 group trajectories, respectively. For continuous-type time-
invariant variables (e.g., age, education, etc.) the minimum effect sizes (f) detectable at 0.80 power 
for 2, 3, and 4 trajectory groups would be 0.150, 0.166, and 0.177, respectively, when using one-
way ANOVA. 
For the specific aim 3 exploring the relationship between DNA variation in candidate genes 
and the distinct latent classes of trajectories for musculoskeletal symptoms, the sample size was 
not justified due to its exploratory nature. 
1.8 HUMAN SUBJECTS 
The dissertation study used de-identified collected data and banked DNA sample from a 
parent study (AIM study). The parent study has been approved by the University of Pittsburgh IRB 
and has completed patient recruitment and DNA banking. An application to the IRB for expedited 
classification of the proposed dissertation study has been approved by the University of Pittsburgh 
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Institutional Review Board (IRB) in August 2018 (PRO18070351; Appendix E). The student has 
completed the following online modules from the Collaborative Institutional Training Initiative 
(CITI) sponsored by the Research Conduct and Compliance Office of the University of Pittsburgh: 
1) Responsible conduct of Research, 2) Human Subjects, and 3) Conflict of Interest. The student 
has received blood borne pathogen training and chemical hygiene training provided by University 
of Pittsburgh. 
Potential risk of the proposed dissertation study includes break of confidentiality of data 
and to anonymity of subjects. In order to minimize the risk, all participants were assigned a unique 
code number under which all data are stored. Security of data was upheld through the use of 
password protection and restricted access to users. Banded DNA samples were assigned a unique 




2.0 SUMMARY OF STUDY 
Musculoskeletal symptoms (including arthralgias, myalgia, and muscle stiffness) are 
common during adjuvant endocrine therapy using aromatase inhibitors (AI), which are generally 
prescribed for 5-10 years for postmenopausal women with hormone-sensitive breast cancer. 
Musculoskeletal symptoms are experienced by up to 85% of AI users, and are the number one 
contributor to the high treatment discontinuation rate (up to 73%). While strategies have been 
proposed to manage musculoskeletal symptoms with AI therapy, there are still no consistently 
effective interventions to prevent or manage the problem, due in large part to the fact that the 
phenotype of musculoskeletal symptoms has not been well-characterized, and the underlying 
mechanisms have not been clearly explicated.  
No current studies have addressed the phenotype of musculoskeletal symptoms with AI 
therapy by examining the inter-individual variability of the problem, precluding the ability to 
screen for high-risk individuals. In addition, the long-term trajectory (after 12 months) at initiation 
of AI therapy is largely unknown. 
Aromatase is expressed across multiple tissues including the brain, muscles, and 
osteoblasts of bone, etc. Estrogen suppression is the main hypothesized mechanism underlying 
musculoskeletal symptoms with AI therapy since AIs block the activity of aromatase and remove 
the protective effects of estrogen on the musculoskeletal system by inhibiting 97-99% of estrogen 
biosynthesis. Our preliminary literature reviews and a biological pathway analysis suggest 
multiple genetic variability in estrogen biosynthesis, AI metabolism, inflammation, and 
preexisting musculoskeletal disorders may all contribute to musculoskeletal symptoms with AI 
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therapy. However, inconsistent evidence about these identified genetic variabilities and the 
collective effects of multiple genetic variabilities requires further examination.  
To address the identified gaps, we conducted this dissertation study to 1) characterize the 
inter-individual variability of the 18-month trajectories of pain and musculoskeletal symptoms, 2) 
determine the associated phenotypic factors (demographic-, clinical characteristics); and 3) 
evaluate the association between phenotypes (pain and musculoskeletal symptoms) and single 
nucleotide polymorphisms (SNPs) among 25 candidate genes (with 46 SNPs).   
2.1 SUMMARY OF MAIN RESULTS, REMAINING GAPS AND FUTURE DIRECTION 
FOR SPECIFIC AIM 1 
(Aim 1): Identify distinct latent classes of 18-month trajectories of pain and musculoskeletal 
symptoms for two cohorts of postmenopausal women (cohort 1: women with early stage breast 
cancer who receive anastrozole; cohort 2: age- and education-matched women without cancer). 
Main results: Three trajectory subgroups were identified for pain severity, pain interference, 
musculoskeletal symptoms, joint pain, and muscle stiffness, respectively. Four distinct trajectory 
subgroups were identified for pain at worst. Two distinct trajectory subgroups were identified for 
the usage of analgesics. 
Our results first supported the existence of inter-individual variability in pain and 
musculoskeletal symptoms with AI therapy for breast cancer. There were a significant proportion 
of women who experienced persistent/or increasing pain/musculoskeletal symptoms at the levels 
of mild/moderate severity. Pain/musculoskeletal symptoms before the initiation of AI therapy is a 
key factor to predict trajectory subgroups in the first 18-month of AI therapy. 
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Remaining gaps and future direction: 
- The long-term changes in pain and musculoskeletal symptoms beyond the first 18 month of 
therapy to the completion of therapy (or even after the completion) are unknown. Extending 
the follow-up period beyond 18 months to after the completion of AI therapy is needed in 
future research. 
- The associations of trajectory subgroup memberships among different phenotypes (e.g., pain 
severity and pain interference) were not examined in the dissertation study. Future 
studies/analysis are needed to further examine the association of subgroup memberships 
across different phenotypes.  
- Several important characteristics (e.g., frequency, quality etc.) of pain and musculoskeletal 
symptoms were not assessed and included in this analysis due to the limitations of the data 
available for analysis. Future studies with a main focus on pain and musculoskeletal 
symptoms with more comprehensive assessment tools should be conducted to better 
phenotype the pain and musculoskeletal symptoms with AI therapy.   
- The structural and functional alterations in deep tissue (joint and muscle) that are related to 
pain are unclear. Future studies are needed to describe the alterations in deep tissue and to 
examine the association between the alterations and patient-reported musculoskeletal pain 
with the AI therapy. 
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2.2 SUMMARY OF MAIN RESULTS, REMAINING GAPS AND FUTURE DIRECTION 
FOR SPECIFIC AIM 2 
 (Aim 2): Determine the phenotypic factors (demographic-, disease-, and individual-related 
characteristics) associated with the membership for the distinct latent classes of trajectories for 
pain and musculoskeletal symptoms. 
Main results: We identified a profile of protective and risk factors across one or more phenotypes. 
The protective factors include older age, receipt of chemotherapy, older first menstrual period age, 
married/partnered, having an administrative level occupation (vs unskilled/unemployed), having 
regular periods for most of life, greater numbers of pregnancies, and having a history of tubal 
ligation. The risk factors include receipt of AI therapy, greater anxiety/pain severity/depressive 
symptoms/fatigue at baseline, and history of arthritis, hysterectomy, or menopausal symptoms. 
 
Remaining gaps and future direction: 
- The limitations of design (cross-sectional design, small sample size, less diverse population 
etc.) of current studies preclude drawing causal-effect relationship and consistent conclusion. 
Further longitudinal studies in a diverse sample with a larger sample size are needed. 
- The collective effects of multiple phenotypic risk factors are not evaluated. A clinically 
useful algorithm to predict whether a patient will develop a persistent/increasing trajectory of 
pain/musculoskeletal symptoms need to be studied and developed in the future.  
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2.3 SUMMARY OF MAIN RESULTS, REMAINING GAPS AND FUTURE DIRECTION 
FOR SPECIFIC AIM 3 
 (Aim 3): Explore the genotypic factors (DNA variation in genes related to estrogen biosynthesis, 
AI metabolism, and musculoskeletal pain) associated with the distinct latent classes of trajectories 
for musculoskeletal symptoms. 
Main results: We identified a profile of protective and risk polymorphisms that were 
associated with mild and/or moderate trajectories of pain and musculoskeletal symptoms (Table 7 
in the manuscript). BDNF rs6265, COMT rs4633 and rs887200, CXCL8 rs4073, ESR2 rs2772163, 
IL1B rs16944, RANKL rs1054016, VDR rs4516035 and rs731236. The risk polymorphisms 
included: CYP19A1 rs1008805, CYP3A4 rs35599367, COMT rs165774, NOS3 rs1799983, OPG 
rs2073618, OPRM1 rs1799971, and TCL1A rs7158782 and rs7159713. We also found a significant 
interaction between NOS3 rs1799983 and OPG rs2073618 when examining the genotypic factors 
of moderate class for musculoskeletal symptoms. 
 
Remaining gaps and future direction: 
- The majority of previous studies (including our study) on the association between genetic 
variance and pain/musculoskeletal symptoms during AI therapy only included a select 
number of candidate genes and SNPs. Examination of the whole genome level is optimal and 
needed to identify additional genes and polymorphisms associated with pain and 
musculoskeletal symptoms.  
- Our study and previous studies did not examine the relationships between genetic variance 
and musculoskeletal pain at the levels of gene expression and epigenetics. Future studies are 
needed to further examine it.  
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2.4 STUDY STRENGTHS AND LIMITATIONS 
This dissertation study adds to the science related to pain/musculoskeletal symptoms 
during AI therapy for breast cancer, including 1) first characterization of interindividual variability 
of pain and musculoskeletal symptoms during AI therapy and extend the follow-up period up to 
18 months; 2) further identification and clarification of phenotypic risk factor with meaningful 
clinical implications; 3) further identification and clarification of a profile of protective and risk 
genetic variance. 
Although the proposed dissertation study has significance for the science of 
musculoskeletal symptoms during AI therapy as well as the clinical application for women with 
breast cancer, there are some limitations. Firstly, the frequency of musculoskeletal symptoms 
during AI therapy was not included since it was not assessed in the parent study. The parent study 
focused on anastrozole and did not include other forms of AI therapy, which may have a different 
profile of musculoskeletal symptoms, although anastrozole is the most commonly prescribed form 
of AI therapy in clinical settings. Thus, the results of this study may not be fully generalized to 
other forms of AI therapy. Moreover, with the exploratory nature of specific aim 3, the sample size 
was not justified when exploring the relationship between DNA variation in candidate genes and 
distinct latent classes of trajectories for musculoskeletal symptoms during AI therapy. Therefore, 
the results for this specific aim will need to be interpreted with caution. 
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3.0 DATA-BASED MANUSCRIPT: PAIN WITH ENDOCRINE THERAPY FOR 
BREAST CANCER: 18-MONTH TRAJECTORIES AND PREDICTORS 
3.1 ABSTRACT 
Musculoskeletal pain (including arthralgias, myalgia, and muscle stiffness) is experienced 
by up to 85% of women undergoing aromatase inhibitor (AI) therapy for breast cancer, and is the 
number one contributor to the high treatment discontinuation rate. The purpose of this ancillary 
study was to examine the trajectories of musculoskeletal pain and related factors during the first 
18 months of AI therapy among postmenopausal women with breast cancer. The parent study, 
Anastrozole Use in Menopausal Women (AIM) study, provided data on pain, musculoskeletal 
symptoms, and candidate phenotypic factors for two cohorts of women (n=380) (cohort 1: women 
with early stage breast cancer who receive anastrozole; cohort 2: age- and education-matched 
women without cancer) at baseline (before initiation of AI therapy for breast cancer cohort), 6, 12, 
and 18 months after baseline. Based on the bio-banked DNA provided by a subgroup of 
participants (n=243) in the parent study, we genotyped 46 single nucleotide polymorphisms 
(SNPs) among the 25 candidate genes which were selected from biological pathway analysis. Our 
results showed that a significant proportion of women experienced mild or moderate level of pain 
and musculoskeletal symptoms in a persistent or linearly increasing manner over the first 18 
months of AI therapy. A profile of protective and risk factors across one or more phenotypes were 
identified. The protective phenotypic factors included older age, receipt of chemotherapy, older 
first menstrual period age, married/partnered, having an administrative level of occupation (vs 
unskilled/unemployed), having regular period for most of life, greater numbers of pregnancies, 
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and having a history of tubal ligation. The phenotypic risk factors included receipt of AI therapy, 
greater anxiety/pain severity/depressive symptoms/fatigue at baseline, and having history of 
arthritis, hysterectomy, or menopausal symptoms. Variations in CYP19A1 (rs1008805) and NOS3 
(rs1799983) were associated with membership across pain and musculoskeletal symptoms. A 
profile of protective and risk polymorphisms was identified. The protective polymorphisms 
included: BDNF rs6265, COMT rs4633 and rs887200, CXCL8 rs4073, ESR2 rs2772163, IL1B 
rs16944, RANKL rs1054016, VDR rs4516035 and rs731236. The risk polymorphisms included: 
CYP19A1 rs1008805, CYP3A4 rs35599367, COMT rs165774, NOS3 rs1799983, OPG rs2073618, 
OPRM1 rs1799971, and TCL1A rs7158782 and rs7159713. 
3.2 INTRODUCTION 
Pain is a leading cause of physical disability among adults with cancer and can be triggered 
or exacerbated by systemic cancer treatments (Fallon et al., 2018). Musculoskeletal symptoms 
(including arthralgias, myalgia, and muscle stiffness) is particularly common during treatment with 
aromatase inhibitor (AI), which is generally prescribed for 5-10 years for postmenopausal women 
with hormone-sensitive breast cancer as an adjuvant endocrine therapy. Among women 
undergoing AI therapy, 48% - 64.3% reported musculoskeletal pain disturbances with daily 
activities (Egawa et al., 2016; Waltman et al., 2009). Our literature review (Zhu et al., 2019) on 
symptoms reported during endocrine therapy has shown that arthralgias and myalgia were the most 
commonly reported symptoms during AI therapy, with occurrences ranging widely from 3.6% to 
89%. Between 25% and 72% of AI users reported joint/muscle stiffness. For those who 
experienced arthralgias and myalgia, 31.5%-46% reported moderate to severe intensity (Chim et 
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al., 2013; Crew et al., 2007; Mao et al., 2009; Presant et al., 2007). The average intensity of 
arthralgias was moderate to severe and ranged from 4.9 to 7.5 out of 10 (as extreme severity) 
(Boonstra et al., 2013; Shi et al., 2013; Servitja et al., 2012; Presant et al., 2007). The onset severity 
of arthralgias was 5.23 on a 10-point scale (Shi et al., 2013). Swenson et al. reported a trend toward 
increasing intensity of musculoskeletal symptoms during the first 6 months after initiation of AI 
treatment (Swenson et al., 2013). It is also reported that arthralgias is the number one contributor 
to the high treatment discontinuation rate; between 13% and 50% of the discontinuation of AI 
therapy is due to AI associated arthralgias (Crew et al., 2007; Dizdar et al., 2009; Henry et al., 
2012). While strategies (e.g., acupuncture, vitamin D supplementation etc.) have been proposed to 
manage pain and musculoskeletal symptoms with AI therapy, there are still no consistently 
effective interventions to prevent or manage the problem, due in large part to the fact that the 
phenotype and risk factors of pain and musculoskeletal symptoms during AI therapy have not been 
well-characterized and its underlying biological mechanisms have not been clearly explicated.  
Among the studies focusing on musculoskeletal symptoms during AI therapy, most 
adopted a cross-sectional design, and the follow-up period of the few longitudinal studies 
completed to date was no more than 12 months (from pre-therapy). There is a need to extend the 
follow-up period beyond the first year of AI therapy to better describe the trajectories of pain and 
musculoskeletal symptoms in women with breast cancer. In addition, among breast cancer 
survivors, inter-individual variability in the experience of several common symptoms during 
surgery and adjuvant therapies have been reported, for example, fear of recurrence (Dunn et al., 
2015), depressive symptoms after surgery (Dunn et al., 2011), pain after chemotherapy (Langford 
et al., 2016), weight changes during chemotherapy (Liu et al., 2014), anxiety pre- and post-surgery 
(Kyranou et al., 2014), and fatigue during and after radiation therapy (Dhruva et al., 2010). The 
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wide range of the prevalence (3.6% - 89%) of musculoskeletal symptoms suggests the possibility 
of inter-individual variability with respect to this symptom as well. However, no studies, to date, 
have examined inter-individual variability in pain and musculoskeletal symptoms during AI 
therapy. 
Estrogen suppression is the main hypothesized mechanism underlying the musculoskeletal 
symptoms associated with AI therapy. AIs block the activity of aromatase, expressed across 
multiple tissues including the brain, muscles, and osteoblasts of bone, etc. and remove the 
protective effects of estrogen on the musculoskeletal system by inhibiting 97-99% of estrogen 
biosynthesis (Fabian, 2007). Current literature reviews (Borrie & Kim, 2017; Sini et al., 2017) and 
our biological pathway analysis (Zhu et al., in press) suggest multiple genetic variabilities in 
estrogen biosynthesis, AI metabolism, inflammation, and preexisting musculoskeletal disorders 
may all contribute to the inter-individual variability of pain and musculoskeletal symptoms with 
AI therapy. However, inconsistent evidence about these identified genetic variabilities and the 
collective effects of multiple genetic variabilities require further examination (Borrie & Kim, 
2017; Zhu et al., in press).  
To address the above gaps, we conducted this study to 1) characterize the inter-individual 
variability of the 18-month trajectories of pain and musculoskeletal symptoms, 2) determine the 
associated phenotypic factors (demographic-, clinical characteristics), and 3) evaluate the 
association between phenotypes (pain and musculoskeletal symptoms) and single nucleotide 
polymorphisms (SNPs) among 25 candidate genes (with 46 SNPs). 
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3.3 METHODS 
This is an ancillary study of the Anastrozole Use in Menopausal Women (AIM) study 
(R01CA107408, PI: Catherine Bender). The design and methods for the parent study have been 
described in detail in our previous publications (Bender et al., 2015). The AIM study was a 
prospective cohort study with a primary aim of examining and comparing the effect of 
anastrozole on cognitive function among four groups of postmenopausal women: women with 
early stage breast cancer who receive chemotherapy plus anastrozole (ChemoAnast), anastrozole 
alone (AnastAlone), chemotherapy only (ChemoOnly), and women without breast cancer who 
were matched on age, and years of education to the breast cancer cohorts. This secondary 
analysis focused on three of the AIM study cohorts: ChemoAnast, AnastAlone, and women 
without breast cancer (Control). Participants were evaluated at baseline (before the initiation of 
AI therapy for breast cancer cohorts), and at 6-, 12-, and 18-month after baseline assessment. 
Inclusion criteria for ChemoAnast and AnastOnly cohorts were: 1) female; 2) diagnosed 
with stage I, II, and IIIa breast cancer based on the Tumor, Node, Metastasis Classification 
System and confirmed by oncologist; 3) eligible to receive either chemotherapy + anastrozole, or 
anastrozole alone; 4) postmenopausal defined as amenorrhea persisting for an entire year, 
oophorectomy, or hysterectomy and age greater than 51 years; 5) maximum age of 75 years; 6) 
able to speak and read English; and 7) completed a minimum of 8 years of education. Exclusion 
criteria for all subjects were: 1) self-report of hospitalization for psychiatric illness within the last 
2 years; 2) a prior diagnosis of neurologic illness; 3) clinical evidence of distant metastases 
including the central nervous system, or 4) prior diagnosis of cancer. The participants were 
recruited from the Comprehensive Breast Care Program of the UPMC Hillman Cancer Center, an 
NCI-designated Comprehensive Cancer Center. The AIM study was approved by the University 
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of Pittsburgh IRB, and all participants provided written informed consent. A subgroup of 
participants (n=283) in the AIM study agreed to provide a blood or saliva sample. The DNA of 
these sample were extracted and bio-banked in a comprehensive Nursing and Basic Science 
Laboratory. New genetic data was generated from the bio-banked DNA samples. 
3.3.1 Measures and instruments 
The baseline characteristics (demographic and clinical) were recorded after the completion 
of surgery for the breast cancer cohorts and at the initial study time point for the control cohort. 
Depression, anxiety, and fatigue were assessed at baseline (pre-therapy) with the Beck Depression 
Inventory (second edition) (Beck, Steer & Carbin, 1988), Profile of Mood States Tension/Anxiety 
and Fatigue/Inertia subscale (Terry et al., 1999) respectively. Pain and musculoskeletal symptoms 
were assessed with the Brief Pain Inventory and Breast Cancer Prevention Trial Symptom 
Checklist at pre- and 6, 12, and 18 months post initiation of adjuvant AI therapy for breast cancer 
cohort and at corresponding timepoints for control cohort. 
The Brief Pain Inventory (BPI) short form was used to assess self-report of severity of pain, 
interference of pain on daily functions, usage of analgesics (including both prescribed and over-
the-counter analgesics) in the past week. The severity of pain (worst, least, average, and right now) 
was assessed by 4 items with a scale ranging from 0 (no pain) to 10 (pain as bad as you can 
imagine). Pain interference with general activity, mood, walking ability, normal work, relations 
with other people, sleep, and enjoyment of life are assessed by 7 items with a scale ranging from 
0 (does not interfere) to 10 (completely interferes). Cronbach’s alpha reliability of BPI has been 
reported ranging from 0.77 to 0.91 (Cleeland & Ryan, 1994).  
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Musculoskeletal symptoms were assessed by the musculoskeletal subscale of the Breast 
Cancer Prevention Trial (BCPT) Symptom Checklist that includes 5 items (general aches and 
pains, joint pains, muscle stiffness, swelling of hands or feet, and numbness or tingling). 
Participants were asked to indicate the presence or absence of each musculoskeletal symptom and 
rate its associated distress on a five-point Likert scale ranging from 0 (not at all) to 4 (extremely). 
Prior studies have demonstrated good reliability and validity with an internal consistency 
reliability exceeding 0.70. The Cronbach’s alpha for all items was reported as 0.81 (Stanton et al., 
2005; Cella et al., 2008; Terhorst et al., 2011). 
3.3.2 Selection of candidate genes and SNPs, and genotyping 
A comprehensive, 3-step literature review with broadened scope was conducted to identify 
genes associated with musculoskeletal symptoms in 1) breast cancer, 2) cancer, and 3) a population 
without cancer (e.g., low back pain, fibromyalgia, arthritis-related pain, knee pain, widespread 
musculoskeletal pain etc.). Studies published through June 2017 were queried using combinations 
of key terms in PubMed. From the literature review, 13 genes were identified related to 
musculoskeletal symptoms with AI therapy for breast cancer, including ESR1, CYP17A1, 
CYP19A1, CYP27B1, CYP2A6, CYP3A4, CYP3A5, IGF1, TCL1A, OPG, RANKL, UGT2B17, and 
VDR. When broadening the review scope to include musculoskeletal symptoms in populations 
with/without cancer, the number of identified genes increased to 72. 
The 72 genes identified from the literature review were entered into a gene-gene pathway 
analysis sing QIAGEN’s Ingenuity® Pathway Analysis (IPA) software, and 23 genes were 
selected based upon the current evidence of their association with musculoskeletal symptoms with 
AI therapy and the numbers of direct and indirect interactions (including binding, inhibiting, acting 
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on, inhibiting and acting on, leading to, and translocating to) with other candidate genes in the 
IPA. The 23 candidate genes are BDNF, CCL2, CXCL8, CYP17A1, CYP19A1, CYP27B1, 
CYP2A6, CYP3A4, CYP3A5, ESR1, ESR2, IGF1, IL1A, IL1B, IL1RN, LIF, MMP13, NOS3, 
TCL1A, OPG (TNFRSF11B), RANKL (TNFSF11), VDR, and WNT5A. Three additional genes 
(COMT, IL-6, and OPRM1) that have been published to be closely associated with chronic pain 
were added to the candidate gene list (Knisely et al., 2019). A total of 26 candidate genes were 
initially selected. Tagging SNPs and literature-driven functional SNPs for these 26 candidate genes 
were selected for investigation. Tagging SNPs were selected using the Phase III HapMap database. 
Tagging SNPs were required to be common (minor allele frequency of ≥ 0.05) in public databases. 
The selection and prioritization of candidate genes, and the process of the ingenuity pathway 
analysis have been previously reported (Zhu et al., 2019). 
Of the 283 participants who provided a blood or saliva sample from the AIM study, 243 
who had complete phenotype and phenotypic factor profile were genotyped and included in the 
genetic analysis. Extracted DNA samples were genotyped with the Sequenom iPLEX 
MassARRAY platform or ABI TaqMan allelic discrimination. To ensure robust genetic 
association analyses, SNPs with call rates of <90%, minor allele frequency of >0.05, or Hardy-
Weinberg estimates with p<0.05 were excluded. Table 5 lists the 46 SNPs among the 25 candidate 
genes that met all the quality control criteria and were included in the genetic analyses. (CYP3A5 
was removed from the candidate gene list because neither the tagging SNP nor functional SNP 
was identified). 
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3.3.3 Statistical analysis 
3.3.3.1 Characterization of the inter-individual variability for the Pain and Musculoskeletal 
Symptoms (Phenotype) 
Participants who 1) had completed more than two timepoint assessments with the BPI 
and BCPT, and 2) had complete profile of candidate risk factors, were included in the final 
analysis. Group-based trajectory modeling (GBTM) (Jones & Nagin, 2007; Nagin & Odgers, 
2010) was performed using SAS (version 9.4, SAS Institute, Inc., Cry, NC) to identify distinct 
latent classes of trajectories for pain experience over the first 18 months of adjuvant AI therapy 
and the corresponding time period for the control cohort. Using GBTM, BPI pain at worst, BPI 
pain severity (average), BPI pain interference (average), subscale of BCPT musculoskeletal 
symptoms (average), BCPT joint pain, BCPT muscle stiffness were modeled as a function of 
time under a censored normal model to identify distinct latent classes of trajectories, separately. 
The usage of analgesics was modeled as function of time under a logit model to identify distinct 
latent classes of trajectory. The number of distinct latent classes of trajectories was determined 
by the Bayesian Information Criteria (BIC), where the best-fitting model has the greatest BIC 
when comparing model BIC using the Bayes factor (Nylund, Asparouhov & Muthen, 2007). The 
shape of each estimated representative average trajectory for each class was determined by 
fitting regression model as polynomials of time (constant [intercept only], linear, quadratic, and 
cubic) and testing whether regression coefficients differ from zero (significance testing with t-
statistics). 
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3.3.3.2 Statistical Analyses of the Phenotypic Factors 
Multivariate multinomial logistic regression was conducted to determine the associated 
phenotypic factors (demographic and clinical characteristics) of trajectory group membership. All 
factors are time invariant. Using predicted trajectory group membership as a categorical variable, 
all factors of interest were screened one at a time using analysis of variance (ANOVA) for 
continuous variables (or Kruskal-Wallis H test if homogeneity of variances was violated), and Chi-
square test (or Fisher exact test if sparse cells are encountered) for categorical variables. Variables 
that were not significant at the 0.30 level in the univariate analysis were not included in the 
multivariate multinomial logistic regression. A backward stepwise approach was used to create a 
parsimonious model. Statistical tests were 2-sided, and only predictors with p < 0.05 were retained 
in the final model. 
3.3.3.3 Statistical Analyses of the Genetic Data 
Allele and genotype frequencies were determined by gene counting. Hardy-Weinberg 
equilibrium was examined by the Chi-square test. Additive, dominant, and recessive genetic 
models were performed to assess the univariate association between each SNP and each trajectory 
group membership (phenotype) by Chi-square test (or Fisher exact test if sparse cells are 
encountered), individually. The genetic model that best fit the data, by maximizing the significance 
of the p-value, was selected for each SNP. Multinomial logistic regression analysis, which 
controlled for significant phenotypic factors (demographic and clinical characteristics) was 
conducted to examine the association between genotype of significant SNPs (selected from 
univariate analysis) and corresponding trajectory group membership (phenotype). A Backward 
stepwise approach was used to build a parsimonious model. Only predictors with p < 0.05 were 
retained in the final parsimonious model. Interactions between significant SNPs identified from 
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multinomial logistic regression were further analyzed to explore the collective effects of 
significant SNPs.  
3.4 RESULTS 
3.4.1 Participant Characteristics 
In total of 380 participants who 1) had completed more than two timepoints’ assessments 
with the BPI and BCPT, and 2) had complete profile of candidate phenotypic risk factors, were 
included in the final analysis. The 380 women were on average 60.6 years of age, Caucasian 
(95.0%), and married/partnered (65.0%). Demographic and clinical characteristics of the 380 
participants are detailed in the Table 6. The study flow diagram is displayed in Figure 2.  
3.4.2 Inter-individual variability for pain and musculoskeletal symptoms 
The GBTM identified three trajectory subgroups for pain severity, pain interference, pain at worst, 
musculoskeletal symptoms, joint pain, and muscle stiffness, respectively. Four distinct trajectory 
subgroups were identified for pain at worst. Two distinct trajectory subgroups were identified for 
the usage of analgesics. The observed and model-estimated subgroups of trajectories for pain and 
musculoskeletal symptoms are listed in the Table 7.  
The three distinct trajectory subgroups for pain severity are: constant no pain (34.2%; 
b[intercept]=-3.47, p<0.01), constant mild pain (45.1%; b[intercept]=1.16, p<0.01), and moderate 
initial pain with linear increase (20.7%; b[intercept]=4.14, p<0.01; b[linear]=0.06, p=0.01). The 
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four distinct trajectory subgroups for pain at worst are: constant no pain (27.7%; b[intercept]=-
4.37, p<0.01), initial no pain with linear increase (7.7%; b[intercept]=-9.69, p<0.01; 
b[linear]=0.82, p<0.01), constant mild pain (29.8%; b[intercept]=1.06, p<0.01), and constant 
moderate pain (34.8%; b[intercept]=3.82, p<0.01). For pain interference, three distinct trajectory 
subgroups are found: constant no interference (47.5%; b[intercept]=-2.55, p<0.01), constant mild 
interference (40.9%; b[intercept]=1.24, p<0.01), and constant moderate interference (11.6%; 
b[intercept]=5.09, p<0.01). For the usage of analgesics, two distinct trajectories are identified: 
constant no use (61.7%; b[intercept]=-2.22, p<0.01), and initial no use with linear increase (38.3%; 
b[intercept]=0.65, p<0.01; b[linear]=0.05, p<0.01). 
The three distinct trajectory subgroups for joint pain are: constant no pain (20.1%; 
b[intercept]=-0.67, p<0.01), mild initial pain with quadratic change (61.2%; b[intercept]=0.89, 
p<0.01; b[linear]=0.08, p<0.01; b[quadratic]=-0.003, p<0.01), and moderate initial pain with 
linear increase (18.7%; b[intercept]=2.75, p<0.01; b[linear]=0.04, p<0.01). For muscle stiffness, 
three distinct trajectory subgroups are identified: constant no (22.3%; b[intercept]=-1.00, p<0.01), 
mild initial stiffness with linear increase (62.8%; b[intercept]=0.76, p<0.01; b[linear]=0.02, 
p<0.01), and moderate initial stiffness with linear increase (14.9%; b[intercept]=2.48, p<0.01; 
b[linear]=0.02, p<0.01). In terms of musculoskeletal symptoms, three distinct trajectory subgroups 
are identified: constant no (49.7%, b[intercept]=0.37, p<0.01), mild initial symptoms with linear 
increase (39.7%, b[intercept]=1.08, p<0.01; b[linear]=0.01, p<0.01), and constant moderate 
symptoms (10.5%, b[intercept]=2.37, p<0.01). 
Figure 3 shows the patterns of trajectories for pain and musculoskeletal symptoms. 
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3.4.3 Phenotypic Predictors Associated with Membership in the Pain and Musculoskeletal 
Symptoms Subgroups 
Table 8 exhibits the socio-demographic and clinical characteristics that differed 
significantly among subgroup membership for pain and musculoskeletal symptoms. Table 9 
summarizes significant phenotypic predictors across subgroup membership of pain and 
musculoskeletal symptoms.  
For BPI pain severity, being a recipient of chemotherapy was associated with 54.2% lower 
odds of belonging to the mild pain severity class. Receipt of AI therapy, history of arthritis, and 
having greater depressive symptoms were associated with a 3.91-, 2.97-, and 1.11-fold increase in 
the odds of belonging in the mild pain severity class, respectively. Being married/partnered and 
having an administrative level of occupation (vs unskilled/unemployed) were associated with 
55.6% and 70.4% lower odds of belonging to the moderate pain severity class. Recipient of AI 
therapy, history of hysterectomy, history of arthritis, greater depressive symptoms, and greater 
fatigue were associated with 5.37-, 3.10-, 10.58-, 1.15-, 1.14-fold increase in the odds of belonging 
in the moderate pain severity class, respectively. 
For BPI worst pain, receipt of AI therapy was associated 4.18-fold increase in the odds of 
belonging in the initial no pain with linear increase subgroup. Greater numbers of pregnancies was 
associated with 28.6% lower odds of belong in the initial no pain with linear increase class. Receipt 
of AI therapy, history of arthritis, and greater depressive symptoms at baseline were associated 
with 3.34-, 1.67-, and 1.04-fold increase in the odds of belonging in the constant mild class, 
respectively. Receipt of AI therapy, history of arthritis, and greater depressive symptoms at 
baseline were associated with 4.83-, 11.23-, and 1.22-fold increase in the odds of belonging in the 
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constant moderate class, respectively. Having a history of tubal ligation was associated with 54.3% 
lower odds of belong in the constant moderate class. 
For BPI pain interference, older age and having an administrative level of occupation (vs 
unskilled/unemployed) were associated with 5.5% and 72.7% lower odds of belonging to the mild 
class of pain interference. Receipt of AI therapy, history of hysterectomy, history of arthritis, 
greater pain severity at baseline, and greater fatigue were associated with 2.23-, 2.02-, 2.33-, 2.33-
, and1.08-fold increase in the odds for belonging in the mild pain interference class, respectively. 
Older age and having an administrative level of occupation (vs unskilled/unemployed) were 
associated with 13.3% and 88.0% lower odds of belonging to the moderate class of pain 
interference. Receipt of AI therapy, history of hysterectomy, history of arthritis, greater depressive 
symptoms, greater anxiety, and greater pain severity at baseline were associated with 4.66-, 4.36-
, 6.86-, 1.21-, 1.11-, and 3.93-fold increase in the odds for belonging in the moderate pain 
interference class, respectively. 
For the usage of analgesics, being married/partnered, having an administrative level of 
occupation (vs unskilled/unemployed), and older age at menarche were associated with 50.2%, 
63.6%, and 24.7% lower odds of belonging to the linear increase usage class. Receipt of AI 
therapy, greater anxiety, greater pain severity at baseline were associated with 4.68-, 1.09-, and 
1.94-fold increase in the odds for belonging in the linear increase usage class. 
For BCPT musculoskeletal symptoms, receipt of AI therapy, history of arthritis, greater 
depressive symptoms, and greater fatigue were associated with 1.93-, 3.23-, 1.08-, and 1.12-fold 
increase in the odds for belonging in the mild class. Having an administrative level of occupation 
(vs unskilled/unemployed) was associated with 74.9% lower odds of belonging to the moderate 
class. Having history of hysterectomy, history of arthritis, greater depressive symptoms, and 
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greater fatigue were associated with 2.89-, 10.10-, 1.16-, and 1.26-fold increase in the odds for 
belonging in the moderate class, respectively.  
For BCPT joint pain, having an administrative level of occupation (vs 
unskilled/unemployed) and regular period for most of life were associated with 75.4% and 63.7% 
lower odds of belonging to the mild class. History of arthritis and greater fatigue were associated 
with 3.16-, and 1.22-fold increase in the odds of belonging in the mild class. Having an 
administrative level of occupation (vs unskilled/unemployed) and regular period for most of life 
were associated with 85.7% and 83.3% lower odds of belonging to the moderate class. History of 
menopausal symptoms, history of arthritis and greater fatigue were associated with 4.62-, 13.66-, 
and 1.40-fold increase in the odds for belonging in the moderate class, respectively. 
For BCPT muscle stiffness, receipt of AI therapy, history of hysterectomy, and greater 
fatigue were associated with 1.96-, 2.64-, and 1.12-fold increase in the odds for belonging in the 
mild class. History of hysterectomy, history of arthritis, greater depressive symptoms, and greater 
fatigue were associated with 2.89-, 5.38-, 1.15-. and 1.29-fold increase in the odds of belonging in 
the moderate class, respectively. 
3.4.4 Genotypic Predictors Associated with Membership in Pain and Musculoskeletal 
Symptoms Subgroups 
Significant associations between SNPs and membership in the pain and musculoskeletal 
symptoms subgroups, adjusted by identified phenotypic factors, are shown in Table 10. Table 11 
summarizes significant genotypic predictors across membership in the pain and musculoskeletal 
symptoms subgroups. 
 49 
For BPI pain severity, carrying 1 or 2 doses of the rare T allele (i.e., GT+TT vs GG) in 
RANKL rs1054016 was associated with 56.2% decrease in the odds of belonging in the mild class. 
Carrying 2 doses of the rare A allele (i.e., AA vs GG+GA) in CYP19A1 rs1008805 was associated 
with 11.27-fold increase in the odds for belonging in the moderate class. Carrying 2 doses of the 
rare G allele (i.e., GG vs GT+TT) in NOS3 rs1799983 was associated with 3.12-fold increase in 
the odds for belonging in the moderate class. For COMT, carrying 2 doses of the rare T allele (i.e., 
TT vs CT+CC) in rs887200 and rs4633 associated with 84.6% and 87.1% lower odds for belonging 
in the moderate class, respectively. 
For BPI pain at worst, carrying 1 or 2 doses of the rare A allele (i.e., GA+AA vs GG) in 
ESR2 rs2772163 was associated with a 90.8% decrease in the odds of belonging in the initial no 
pain with linear increase class. Carrying 1 or 2 doses of the rare A allele (i.e., GA+AA vs CC) in 
LIF rs737812 was associated with 3.78-fold increase in the odds of belonging in the initial no pain 
with linear increase class. Carrying 2 doses of the rare G allele (i.e., GG vs AA) in TCL1A 
rs7158782 and rs7159713 was associated with 23.9- and 25.07-fold increase in the odds of 
belonging in the initial no pain with linear increase class. Carrying 1 or 2 doses of the rare G allele 
(i.e., AG+GG vs AA) in VDR rs731236 was associated with 55.6% decrease in the odds of 
belonging in the constant mild pain class. Carrying 2 doses of the rare T allele (i.e., TT vs AA+AT) 
in CXCL8 rs4073 was associated with 79.6% decrease in the odds of belonging in the constant 
moderate class. Carrying 2 doses of the rare A allele (i.e., AA vs GG+GA) in CYP19A1 rs1008805 
was associated with 4.32-fold increase in the odds of belonging in the constant moderate pain class. 
Carrying 2 doses of the rare C allele (i.e., CC vs TT) in VDR rs4516035 was associated with 78.2% 
decrease in the odds of belonging in the constant moderate pain class. 
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For BPI pain interference, carrying 1 or 2 doses of the rare C allele (i.e., TC+CC vs TT) in 
VDR rs4516035 was associated with 57.4% lower odds for belonging in the mild class. 
For BCPT joint pain, carrying 1 or 2 doses of the rare T allele (i.e., CT+TT vs CC) in 
BDNF rs6265 was associated with 56.0% lower odds for belonging in the mild class.  
For BCPT muscle stiffness, carrying 1 or 2 doses of the rare A allele (i.e., GA+AA vs GG) 
in IL1A rs3783521 was associated with 2-fold increase in odds for belonging in the mild class. 
Carrying 2 doses of the rare G allele (i.e., GG vs AG+AA) in IL1B rs16944 was associated with 
55.2% lower in odds for belonging in the mild class. Carrying 1 or 2 doses of the rare G allele (i.e., 
AG+GG vs AA) in OPRM1 rs1799971 was associated with 4.06-fold increase in odds for 
belonging in the mild class. 
For BCPT musculoskeletal symptoms, carrying 2 doses of the rare A allele (i.e., AA vs 
GG) in CYP3A4 rs35599367 was associated with 4.997-fold increase in odds for belonging in the 
mild class. Carrying 2 doses of the rare A allele (i.e., AA vs TA+TT) in IL1RN rs380092 was 
associated with 46.1% lower in odds for belonging in the mild class. Carrying 2 doses of the rare 
G allele (i.e., GG vs AG+AA) in VDR rs731236 was associated with 73.6% lower in odds for 
belonging in the mild class. Carrying 2 doses of the rare A allele (i.e., AA vs GG+GA) in CYP19A1 
rs1008805 was associated with 6.13-fold increase in the odds for belonging in the moderate class. 
Carrying 2 doses of the rare G allele (i.e., TG+GG vs TT) in NOS3 rs1799983 was associated with 
5.14-fold increase in the odds for belonging in the moderate class. Carrying 2 doses of the rare C 
allele (i.e., CC vs GC+GG) in OPG rs2073618 was associated with 4.50-fold increase in the odds 
for belonging in the moderate class. A significant interaction between NOS3 rs1799983 and OPG 




3.5.1 Inter-individual variability of pain and musculoskeletal symptoms (Phenotype) 
Long-term longitudinal data are needed to understand the course and inter-individual 
variability of pain and musculoskeletal symptoms during the AI therapy. The number of 
longitudinal studies focusing on pain and musculoskeletal symptoms during AI therapy is very 
limited, as most of studies adopted a cross-sectional design. Previous longitudinal studies have 
relatively small sample sizes and a short follow-up period of 12 months post-initiation of therapy. 
Most previous studies focused on identifying the time of onset of pain and musculoskeletal 
symptoms, only a very few studies have reported pain severity and interference. Our study is the 
first to characterize the inter-individual variability of pain (severity and interference) and 
musculoskeletal symptoms among women with breast cancer undergoing the AI therapy. We 
extended the trajectories over the first 18 months of AI therapy, with a comparison cohort of 
postmenopausal women without breast cancer.  
3.5.1.1 General pain  
Only a few studies of pain with AI therapy have reported pain severity and interference, 
since most studies mainly focused on the onset of pain (occurrence). In our study, the group means 
of BPI pain severity and interference are mild and stable over the 18 months. The ranges of the 
group mean of pain severity and interference across the four-time assessment points are 1.56-1.92 
and 1.22-1.40. This finding is consistent with other clinical studies that have reported the BPI pain 
scores, although the follow-up period of other studies is less than 12 months. Swenson et al. 
reported mild pain severity and interference at pretreatment (BPI severity [mean]=1.66 out of 10; 
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BPI interference [mean]=2.31) and at 6 months after AI initiation (BPI severity [mean] =1.08; BPI 
interference [mean]=1.75) (Swenson et al., 2013). 
Except those who never developed pain during the AI therapy, the severity and interference 
of pain during AI therapy are persistent. We identified persistent mild and moderate trajectories 
for both pain severity and interference across the first 18 months of AI therapy. In our results, 
45.1% of participants had constant mild pain severity, and 20.7% had moderate initial pain with 
linear increase over the 18 months. Although none of previous studies reported inter-individual 
trajectory patterns of pain, some demonstrated a similar trend. Laroche et al. also found that most 
of the pain (57%) that developed during the first 12 months of AI therapy was persistent and with 
high severity (60 out of 100) (Laroche et al., 2014). Singer et al. reported a mild increase trend in 
pain by a mean of 14.6mm (out of 100) (Singer et al., 2012). In addition, our study first examined 
the interindividual variability in the domain of pain severity at worst and identified a distinct 
trajectory of initial no pain with linear increase (7.7%) over the first 18 months. This subgroup 
trajectory is unique to the worst pain domain compared to the general pain severity domain. It is 
of utmost importance to identify this higher-risk subgroup in clinical practice. However, 
considering the relatively small percentage of participants in this class (7.7%), this finding needs 
to be further examined and confirmed by future research and clinical observation. For pain 
interference, we found 40.9% and 11.6% of participants reported constant mild and moderate 
interference respectively, which indicates that the pain interference during the AI therapy is 
persistent. Without effective strategies to manage pain, patients undergoing AI therapy may not 
effectively manage the pain and its related detrimental impact on daily lives by themselves.  
In our study, 34.2% and 47.5% of participants never reported pain and interference with 
pain over the 18 months of therapy. In future research, it will be important to investigate why some 
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women may be free of pain during the AI therapy, and why a smaller subgroup of women who 
developed pain may experience no interference with pain. This finding also further introduces the 
importance of investigating a risk factor profile to predict the high-risk subgroup population. 
3.5.1.2 Usage of analgesics 
While analgesics (mostly nonsteroidal anti-inflammatory drugs) are authorized for use to 
manage pain with AI therapy, the outcome is not fully satisfactory. In our findings, 38.3% of 
participants used analgesics increasingly over the 18 months of therapy, nevertheless, we still 
identified a moderate trajectory of pain severity with linear increase trend and a moderate trajectory 
of pain interference remaining at a constant level. The percentage of our participants using 
analgesics was a bit less than the results from Shi’s study, which reported that 50% of those with 
joint pain and 40% of those without joint pain used analgesia at 6 months after initiation of AI 
therapy (Shi et al., 2013). Concerns have been raised that degeneration of joints and deep tissues 
associated with AI use may be masked by opioid use (Cella & Fallowfield, 2008). 
3.5.1.3 Musculoskeletal symptoms 
In our study, the group means of BCPT musculoskeletal symptoms are mild and stable over 
the 18 months (Table 2). The ranges of group mean of BCPT musculoskeletal subscale across the 
four-time assessment points is 0.83-0.99. This finding is consistent but a bit lower than the results 
reported by Swenson. Swenson et al. reported mild musculoskeletal symptoms as measured by 
BCPT symptom checklist at pretreatment (mean=1.08±0.85 out of 4) and at 6 months after AI 
initiation (mean=1.7±1.18) (Swenson et al., 2013). 
In our study, 79.1% of participants reported persistent joint pain over the course of 18 
months: 61.2% of participants had mild joint pain at the initial assessment, prior to the initiation 
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of AI therapy with quadratic changes (increasing over the first 12 months and then decreasing from 
12 to 18 months), and 18.7% had moderate initial joint pain with a linear increase over the 18 
months post-initiation of therapy. Most previous studies reported that the average/median onset 
time of joint pain is before the first 3 months of AI initiation (6 weeks by Castel et al., 7 weeks by 
Shi et al. first 3 months by Mao et al.) (Castel et al., 2013; Shi et al., 2013; Mao et al., 2009). From 
the few studies that reported severity of pain, Mao reported that more than 60% of participants 
reported joint pain as moderate or severe (Mao et al., 2009). This is dramatically higher than our 
results related to pain severity (18.7%). Several reasons may explain this difference: 1) Mao 
adopted a cross-sectional design our study used a longitudinal design. During our longitudinal 
follow-up, those who experienced intolerable joint pain may be withdrawn from the parent study 
as they may have discontinued AI use; 2) in our study, including a subgroup of women without 
breast cancer who were not undergoing AI therapy may attenuate the proportion of subpopulation 
with more severe musculoskeletal symptoms. Castel reported that by week 6 of AI therapy, women 
experienced a significant increase in severity of their joint pain. Castel’s trajectory analysis 
indicated that joint pain severity worsened over the first year of AI therapy, which is consistent 
with our findings (Castel et al., 2013). By extending the follow-up period to 18 months, we further 
demonstrated that, from 12 to 18 months, joint pain severity of 18.7% participants continued to 
worsen, while the pain severity of 61.2% of our participants decreased. Laroche et al., also found 
that some patients (22%) developed diffuse pain after 12 months of AI therapy, which leads to the 
hypothesis that estrogen deprivation may act on joints and tendons more rapidly than on the central 
nervous system, leading to a lag in the time for development of diffuse pain (Laroche et al., 2014). 
Both our findings and those of Laroche’s suggest that women with AI therapy should undergo pain 
evaluation in a long-term manner over the course of AI therapy. 
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3.5.2 Phenotypic factors to pain and musculoskeletal symptoms 
Phenotypic risk factors for pain and musculoskeletal symptoms are not well characterized. 
Current reported phenotypic risk factor profiles are mostly from cross-sectional studies and few 
longitudinal studies with relatively small sample sizes have been reported. There is inconclusive 
evidence for the reported risk factors. One of the main aims of our study was to examine the 
phenotypic risk factors for the individual variability of pain and musculoskeletal symptoms during 
AI therapy.  
In our study, profiles of protective and risk factors across one or more phenotypes were 
identified. The protective factors include older age, receipt of chemotherapy, older age at first 
menstrual period, married/partnered, having an administrative level occupation (vs 
unskilled/unemployed), having regular periods for most of their lives, greater numbers of 
pregnancies, and having a history of tubal ligation. Risk factors include receipt of AI therapy, 
greater anxiety/pain severity/depressive symptoms/fatigue at baseline, and a history of arthritis, 
hysterectomy, or menopausal symptoms (Table 9).  
In terms of demographic characteristics, we found that older age, currently 
married/partnered, and having an administrative level of occupation (vs unskilled/unemployed) 
were associated with an increase in odds of belonging to the class of constant no symptom in one 
or more phenotypes. Women who were older were less likely to belong to the mild or moderate 
trajectory of pain interference. This result is consistent with results from the studies of Menas et 
al. and Mao et al. 2011 (Menas et al., 2012; Mao et al, 2011), which showed that younger age was 
associated with less joint pain. In our results, women who were currently married were less likely 
to belong to the moderate trajectory of pain severity and more likely to not use analgesics during 
therapy. In our study, having an administrative level of occupation was a protective factor across 
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multiple phenotypes including pain severity, pain interference, usage of analgesics, joint pain, and 
musculoskeletal symptoms. However, Shi and Mao’s studies reported that status of marriage and 
employment were not significantly associated with pain and musculoskeletal symptoms during AI 
therapy (Shi et al. 2013; Mao et al., 2009). The differences in demographic profiles between the 
studies may be the result of limited sample size of Shi’s study and cross-sectional design for Mao’s 
study. In addition, Shi and Mao did not examined the type of employment in their examination the 
employment as a predictor (Shi et al. 2013; Mao et al., 2009). 
We found that receipt of chemotherapy was associated with increase in the odds of 
belonging to the constant no trajectory in pain severity. This result is different from others. Four 
studies reported that receipt of chemotherapy was a risk factor for the development of joint pain 
(Mao et al., 2011; Crew et al., 2007; Wang et al., 2013, Ohsako et al., 2006). However, three other 
studies demonstrated no significant association between joint pain and receipt of chemotherapy 
(Menas et al., 2012; Castel et al., 2013; Shi et al., 2013). Considering the relatively small sample 
size of these studies, these differences emphasize the need to further examine the effect of 
chemotherapy on pain and musculoskeletal symptoms in a diverse sample with a larger sample 
size. 
Consistent with other studies, our findings confirmed that shorter hormonal exposure (older 
first menstrual period age) and stable hormonal status (regularity of periods for most of life, no 
history of menopausal symptoms, no history of hysterectomy) were associated with less pain and 
musculoskeletal symptoms. Mao and Castel’s studies both reported that less time since last 
menstrual period (< 5 years) and less baseline severe menopausal symptoms were associated with 
less severe joint pain over the course of AI therapy (Mao et al., 2009; Castel et al., 2013). Laroche 
also reported that longer menopausal duration was a key predictive factor for the development of 
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pain during AI therapy (Laroche et al., 2014). Shi et al. reported that in the first 6 weeks of AI 
therapy, hormonal related symptoms (e.g., hot flashes, vaginal dryness, and decreased sexual 
activity) were positively associated with the emergence of joint pain (Shi et al., 2013). These 
findings confirmed the important role of estrogen suppression underlying the development and 
worsening the pain and musculoskeletal symptom during AI therapy. 
We found that higher levels of psychological symptoms (anxiety, depression) and fatigue 
at baseline were associated with greater pain and musculoskeletal symptoms. Among the 
population of women with AI therapy, Laroche first demonstrated that psychological factors (e.g., 
greater anxiety at baseline, some personality traits) may be important predictors of pain (Laroche 
et al., 2014). In Shi et al.’s study, persistent fatigue was positively related to the presence of joint 
pain (Shi et al., 2013). Taken together, our findings reiterate the importance of assessment of pain 
within the context of psychological symptoms and fatigue in the clinical practice.  
As all of our trajectory patterns in pain and musculoskeletal symptoms were distinctive 
from other since the baseline assessment, we observed that baseline pain and musculoskeletal 
symptoms were of utmost importance to determine subgroup membership. This observation is 
consistent with Shi and Henry’s findings. In Shi’s study, baseline pain was proven to be the only 
significant predictor of the development of joint pain during AI therapy, after adjustment for other 
covariates. Shi et al. reported that patients who experienced pain at baseline had 5 times the risk 
of developing joint pain (HR=5.55) compared to those who did not experience pain at baseline 
(Shi et al., 2013). Henry et al reported that patients with baseline pain were more likely to 
discontinue AI therapy due to intolerable symptoms (Henry et al., 2012). Additional research is 
needed to replicate this finding. This observation also has a particular implication for clinical 
practice, indicating assessment of pain and musculoskeletal symptoms before the initiation of AI 
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therapy is important to predict and select subgroups of women at higher risk to develop pain and 
musculoskeletal symptoms. 
In our study, we found that history of arthritis (including osteoarthritis and rheumatoid 
arthritis) was a strong risk factor for the development of a mild and/or moderate trajectory across 
many phenotypes (worst pain severity, pain severity [mean], interference, join pain, muscle 
stiffness, and musculoskeletal symptoms). Castel also reported that preexisting joint-related 
comorbidity at baseline was a significant risk factor (OR=1.71) of more severe joint pain over the 
course of AI therapy (Castel et al., 2013).  
3.5.3 Discussion on genotypic factors 
The associations between variations in genes and inter-individual variability of pain and 
musculoskeletal symptoms are not well investigated. In our exploratory analysis, we identified a 
profile of protective and risk polymorphisms that are associated with mild and/or moderate 
trajectories of pain and musculoskeletal symptoms with AI therapy (Table 11).  The protective 
polymorphisms include: BDNF rs6265, COMT rs4633, COMT rs887200, CXCL8 rs4073, ESR2 
rs2772163, IL1B rs16944, RANKL rs1054016, VDR rs4516035 and VDR rs731236. The risk 
polymorphisms include: CYP19A1 rs1008805, CYP3A4 rs35599367, COMT rs165774, NOS3 
rs1799983, OPG rs2073618, OPRM1 rs1799971, and TCL1A rs7158782 and 7159713. 
3.5.3.1 Polymorphisms associated with multiple phenotypes 
In our study, variations in CYP19A1 (rs1008805) and NOS3 (rs1799983) were associated 
with membership across pain severity and musculoskeletal symptoms.  
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Gene CYP19A1 is involved in regulation of the production and action of estrogen. The 
CYP19A1 gene encodes aromatase, which is a critical enzyme to catalyze the biosynthesis of 
estrogen. Our findings indicate that carrying 2 doses of the rare A allele (i.e., AA vs GG+GA) in 
CYP19A1 rs1008805 was associated with 11.27- and 6.13-fold increase in the odds for belonging 
in the moderate class in pain severity and musculoskeletal symptom, respectively. This result is 
consistent with Gervasini et al, who reported that CYP19A1 rs1008805 was associated with 
arthralgias in 110 postmenopausal women with breast cancer treated with anastrozole (Gervasini 
et al., 2017). CYP19A1 is a highly polymorphic gene. Other polymorphisms in CYP19A1 have 
been associated with joint pain and musculoskeletal symptoms during AI therapy as well. From 
390 Caucasian women with AI therapy for breast cancer, Mao et al. found that people who carry 
at least one (TTTA)7 repeat alleles in rs60271534 were at higher risk of self-reported occurrence 
of arthralgias, whereas people carrying one or more (TTTA)8 repeat alleles had lower risk (Mao et 
al., 2011). Other SNPs being examined but with no significant results in Mao et al.’s study included 
rs10046, rs749292, rs727479, and rs1157899.  In a study of 109 Korean women with breast cancer 
under treatment with letrozole, Park et al. reported that the M_3_5 haplotype (composed of 
rs12148604, rs4646, rs10046, rs700519, rs4324076, rs700518, rs3759811, rs727479, rs4775936, 
rs10459592, rs767199, rs10519297, rs1062033, rs2008691, rs1008805, rs17523527) in CYP19A1 
was associated with self-reported occurrence of bone pain (Park et al., 2011). In a study of 737 
Dutch patients under treatment with exemestane for breast cancer, homozygous CYP19A1 
rs934635-AA genotype was significantly associated with occurrence, but not severity, of 
musculoskeletal adverse events (including arthralgia, arthritis and osteoarthritis, myalgia, and 
other musculoskeletal problems) (Fontein et al., 2014). 
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Carrying 2 doses of the rare G allele (i.e., GG vs TT+TG) in NOS3 rs1799983 was 
associated with 3.12- and 5.14-fold increase in the odds for belonging in the moderate class for 
pain severity and musculoskeletal symptoms, respectively. Variation in NOS3 gene has not been 
reported to be associated with pain or musculoskeletal symptoms during AI therapy in current 
literature. NOS3 gene encodes nitric oxide synthase 3 (NOS3), which is an important enzyme to 
synthesize nitric oxide (NO), primarily in the vascular endothelium, a monolayer of flat cells lining 
in the interior surface blood vessels. Therefore, the NOS is playing an essential role in the 
maintenance of function of the cardiovascular system. There is a growing body of evidence 
suggesting that NO is involved in skeletal muscle glucose uptake, control of skeletal muscle 
structure/function, skeletal muscle fiber type conversion, and mitochondrial ATP production and 
oxygen consumption in skeletal muscles (Gao, 2010; Martins et al., 2012). Although there is not 
a direct evidence to link the function of NOS3 to pain and musculoskeletal symptoms, there is 
accumulative but inconclusive evidence to show the linkage between polymorphisms of NOS3 and 
rheumatoid arthritis in both Caucasian and Chinese populations (Gonzalez-Gay et al., 2009; Nagy 
et al., 2010; Bunjevacki et al., 2016; An et al., 2012).  
3.5.3.2 Synergetic effect between NOS3 and OPG 
We found a significant interaction between NOS3 rs1799983 and OPG rs2073618 when 
exploring the genotypic factors of moderate class for musculoskeletal symptoms. We firstly found 
that carrying 2 doses of the rare C allele (i.e., CC vs GC+GG) in OPG rs2073618 was associated 
with 4.50-fold increase in the odds for belonging in the moderate class for musculoskeletal 
symptoms. This result is consistent with other studies. Litermans et al. found that OPG rs2073618 
was significantly associated with the occurrence of musculoskeletal toxicity and severity of pain 
during AI therapy (Lintermans et al., 2016). This association was confirmed in Chinese Han 
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women with breast cancer as well (Wang et al., 2015). However, when we examined the interaction 
between NOS3 rs1799983 and OPG rs2073618, their independent main effects became 
nonsignificant and a strong significance appeared. This finding suggests that some interactions 
between NOS3 rs1799983 and OPG rs2073618 confer an increased risk of developing moderate 
trajectory of musculoskeletal symptoms. The synergetic effect between NOS3 rs1799983 and OPG 
rs2073618 and its underlying mechanisms needs to be further examined in future studies. 
3.6 CONCLUSION 
Several limitations should be noted when interpreting the results of the present study. 
Firstly, with few African American women enrolled included in this analysis, lack of variation 
precluded examination of race as a risk factor and limited the generalizability of our results beyond 
the Caucasian population. Secondly, the use of analgesics was authorized in participants, thus our 
results may underestimate the actual severity of pain and musculoskeletal symptoms. Furthermore, 
the main focus of the parent study was not on the assessment of pain, thus the quality, severity and 
interference of pain at each specific body site was not phenotyped. In addition, this study included 
a select number of candidate genes and SNPs. Examination of the whole genome level is optimal 
and needed to replicate our findings and to identify additional genes and polymorphisms associated 
with pain and musculoskeletal symptoms.  
This study is the first to characterize the inter-individual variability of pain and 
musculoskeletal symptoms during AI therapy for breast cancer. Our results show that a significant 
proportion of women experienced mild or moderate level of pain and musculoskeletal symptoms 
in a persistent manner over the first 18 months of AI therapy. A profile of protective and risk 
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factors across one or more phenotypes are identified. The protective phenotypic factors include 
older age, receipt of chemotherapy, older first menstrual period age, married/partnered, having an 
administrative level of occupation (vs unskilled/unemployed), having regular period for most of 
life, greater numbers of pregnancies, and having a history of tubal ligation. The phenotypic risk 
factors include receipt of AI therapy, greater anxiety/pain severity/depressive symptoms/fatigue at 
baseline, and history of arthritis/hysterectomy/menopausal symptoms. Variations in CYP19A1 
(rs1008805) and NOS3 (rs1799983) were associated with membership across pain severity and 
musculoskeletal symptoms. A possible synergetic effect between NOS3 rs1799983 and OPG 
rs2073618 was identified. Additional research is warranted to replicate this interaction among 
breast cancer survivors. 
There are remaining gaps in the science of pain and musculoskeletal symptoms with AI 
therapy. Firstly, during the 5-10 years’ course of AI therapy, the long-term changes of pain and 
musculoskeletal symptoms beyond the first 18 months to the completion (or even after the 
completion) are unknown. Extending the follow-up period beyond 18 months to after the 
completion of AI therapy is needed in the future study. Secondly, the limitation of design (cross-
sectional design, small sample size, less diverse population etc.) of current studies preclude 
drawing causal-effect relationship and consistent conclusion. Further longitudinal studies in a 
diverse sample with a larger sample size are needed. In addition, the majority of previous studies 
(including our study) on the association between genetic variance and pain/musculoskeletal 
symptoms during AI therapy only included a select number of candidate genes and SNPs. 
Examination of the whole genome level is optimal and needed to identify additional genes and 
polymorphisms associated with pain and musculoskeletal symptoms. 
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Appendix A TABLES AND FIGURES IN PROPOSAL 
Appendix Table 1 Search terms for literature review on musculoskeletal symptoms during AI therapy for 
breast cancer 








Terms for Musculoskeletal 
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• Breast Cancer 
• Breast 
Neoplasm 
• Aromatase Inhibitors 
• Antineoplastic Agents 
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Appendix Table 2 Studies included in literature review on musculoskeletal symptoms for breast cancer 
Author, 
Year 
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Patient Interview  Recently Occurrence  
Egawa et 
al., 2016 
Japan Longitudinal (pre- 
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Questionnaire - Frequency 
Distress 
Gallicchio 
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USA Longitudinal (pre- 
and 3, 6 months 
post-AI, n=95) 
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2014 
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Appendix Table 3 Occurrence, intensity, and distress of musculoskeletal symptoms for breast cancer 
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• 62.1%/45.7% (AI/TAM) 
(Aiello Bowles et al., 2012)  
• 22%/12% (AI/TAM) 
(Garreau, 2006) 
• 15%/25% (AI/TAM) 
(Hu, 2016) 
• Mean=4.9 out of 10 
(Boonstra, 2013) 
• Mean=5.23 out of 10 
(Shi, 2013) 
• Median=7.5 out of 10 
1-4 out of 10: 14% 
5-7 out of 10: 16% 
8-10 out of 10: 30% 
(Presant, 2007) 
• 34.6% have  4 (out of 10) pain at 
worst 
(Chim, 2013) 
• 31.5% moderate to severe 
(Crew, 2007) 
• 54 out of 100 
(Kyvernitakis, 2014) 
• 31.5%  moderate 
• 12.2%  severe 
(Mao, 2009) 
• Grade 1: 4% 
Grade 2: 0% 
Grade 3: 2% 
(by CTCAE 3.0) 
(Ohsako et al., 2006)  
• Pre: mean=2.75 out of 10 
(Servitja, 2012) 
• 1M: 0.341/0.284/0.219/0.227 
• 6M: 0.552/0.476/0.467/0.368 
(AUSCAN/WOMAC/QuickD
ASH/BPI: standardized mean 
difference to baseline) 
(Swenson, 2013) 
 
• Mean=3.29 out of 10 
(Shi, 2013) 




• 1M: 0.274/0.272 (BCPT/BPI) 
6M: 0.62/0.282 (BCPT/BPI) 
(standardized mean 
difference to baseline) 
(Swenson, 2013) 
• 48% 
7% (interference only with 
athletic activity) 
31% (interference with 
function but not ADLs) 




• Pre: 26.1% 
• 3M: 38.8% 
• 6M: 46.3% 
• 9M: 49.5% 
• 12M: 54.4% 
(Egawa, 2016) 
• 89%/65% (AI/TAM) 
(Litermans, 2014) 




















• 29%  moderate 
(Crew, 2007) 
• Grade 1: 17% 
Grade 2: 2% 
Grade 3: 6% 
(by CTCAE 3.0) 
(Ohsako et al., 2006)  









• 47%/32% (AI/TAM) 
(Lintermans, 2014_2) 
  












Appendix Table 4 Phenotypic factors associated with musculoskeletal symptoms for breast cancer 
 Phenotypic factors 
Study with 
Significant results 





BMI=25-30 (vs <25) Crew (2007) 0.33 (0.14, 0.74)  Shi (2013)  
Mao (2011) 
Prior tamoxifen therapy Crew (2007) 0.40 (0.19, 0.87)   
Sexual functioning Laroche (2014)    
Time since last menstrual 
period (<5 years) 
Mao (2009)  
Mao (2011) 
3.39 (1.21, 9.44)  
Age  Menas (2012) 
Mao (2011)  
 Mao (2009)  
Shi (2013) 
Less baseline severe 
menopausal symptoms 
Castel (2013)  0.97 (0.95, 0.99)  
Menopause duration Laroche (2014)    
Severe breast symptoms Laroche (2014)    
Prior chemotherapy Mao (2011)  
Crew (2007)  
Wang (2013) 
4.08 (1.58, 10.57) Mao (2009) 
Menas (2012)  
Castel (2013)  
Shi (2013) 
Joint-related comorbidity Castel (2013) 1.71 (1.12, 2.61)  
Presence of pain at baseline Shi (2013) 10.66 (1.51, 75.89)  
Vitamin D insufficiency Waltman (2009)   
Weight gain since breast 
cancer 
Su (2010)  2.15 (1.04, 4.42) Mao (2009)  
Race (White vs nonwhite)   Mao (2009)  
Shi (2013) 
Employment   Mao (2009)  
Shi (2013) 
# of comorbidities   Mao (2009)   
Marital status   Shi (2013) 










Prior chemotherapy Ohsako (2006)   









Appendix Table 5 Candidate genes and SNPs 
Gene SNP Position Chr MAF Alleles 
BDNF rs6265 27658369 11 0.201 C>T 
CCL2 rs4586 34256250 17 0.458 T>C 
CXCL8 rs4073 73740307 4 0.478 A>T 
CYP17A1 rs4919683 102825368 10 0.446 C>A 
 rs4919687 102835491 10 0.187 G>A 
CYP19A1 rs10046 51210789 15 0.362 G>A 
 rs752760 51339282 15 0.368 C>T 
 rs1008805 51257402 15 0.353 G>A 
 rs934635 51186580 15 0.123 G>A 
 rs4646 51210647 15 0.336 A>C 
CYP27B1 rs4646536 57764205 12 0.410 A>G 
 rs10877012 57768302 12 0.349 G>T 
CYP2A6 rs28399433 40850474 19 0.128 A>C 
 rs1801272 40848628 19 0.009 A>T 
CYP3A4 rs35599367 99768693 7 0.015 G>A 
ESR1 rs9322336 151879295 6 0.236 C>T 
ESR2 rs4986938 64233098 14 0.260 C>T 
 rs1152582 64225912 14 0.311 G>C 
 rs2772163 64226667 14 0.202 G>A 
IGF1 rs5742612 102481086 12 0.115 A>G 
 rs6214 102399791 12 0.427 C>T 
IL1A rs3783521 112786000 2 0.339 G>A 
IL1B rs16944 112837290 2 0.491 A>G 
 rs1143633 112832890 2 0.311 C>T 
IL1RN rs4251961 113116890 2 0.242 T>C 
 rs380092 113131323 2 0.443 T>A 
LIF rs929271 30242237 22 0.294 T>G 
 rs737812 30243121 22 0.279 C>A 
MMP13 rs597315 102957055 11 0.325 A>T 
NOS3 rs1799983 150999023 7 0.176 T>G 
TCL1A rs11849538 95709641 14 0.253 C>G 
 rs7158782 95702794 14 0.366 A>G 
 rs7159713 95703240 14 0.366 A>G 
 rs2369049 95705514 14 0.324 A>G 
OPG 
(TNFRSF11B) 
rs2073618 118951813 8 0.333 G>C 
 rs2073617 118952044 8 0.378 G>A 
RANKL 
(TNFSF11) 
rs1054016 42607866 13 0333 G>T 
VDR rs739837 47844438 12 0.494 G>T 
 rs731236 47844974 12 0.277 A>G 
 rs4516035 47906043 12 0.177 T>C 
WNT5A rs1829556 55467147 3 0.466 T>C 
COMT rs887200 19976143 22 0.366 C>T 
 rs165774 19965038 22 0.203 G>A 
 rs4633 19962712 22 0.371 C>T 
IL-6 rs1800795 22727026 7 0.141 C>G 








Appendix B TABLES AND FIGURES IN MANUSCRIPT 
Appendix Table 6 Socio-demographic and clinical characteristics of participants at baseline (n=380) 






Age, mean (SD) 61.4 (6.1) 59.0 (5.8) 60.6 (6.07) 
Caucasian (yes, %) 242 (96.8) 119 (91.5) 361 (95.0) 
Currently Married/Partnered, (yes, %) 173 (69.2) 74 (56.9) 247 (65.0) 
Occupation 
Level 1 (administrative) 
Level 2 (skilled) 













First Menstrual period Age  12.3 (1.4) 12.7 (1.5) 12.4 (1.5) 
# of Children, mean (SD) 2 (1) 2 (1) 2 (1) 
# of Pregnant, mean (SD) 2 (2) 2 (2) 2 (2) 
Hormonal Replacement Therapy (yes, %) 109 (43.6) 56 (43.1) 165 (43.4) 
Birth Control Pills (yes, %) 175 (70.0) 97 (74.6) 272 (71.6) 
Hysterectomy (yes, %) 63 (25.2) 25 (19.2) 88 (23.2) 
Oophorectomy (yes, %) 46 (18.8) 21 (16.2) 67 (17.9) 
History of Menopause Symptoms (yes, %) 200 (80.0) 106 (81.5) 306 (80.5) 
Regularity of Periods (yes, %) 217 (86.8) 109 (83.8) 326 (85.8) 
Pregnancy (yes, %) 206 (82.4) 109 (83.8) 315 (82.9) 
Tubal Ligation (yes, %) 80 (32.0) 39 (30.0) 119 (31.3) 
History of Arthritis (yes, %) 95 (38.0) 26 (20.0) 121 (31.8) 
Baseline BDI II Total, mean (SD) 5.7 (5.4) 4.8 (5.8) 5.4 (5.5) 
Baseline POMS Tension-Anxiety, mean (SD) 6.7 (5.1) 6.0 (5.0) 6.5 (5.1) 










Chemotherapy (yes, %) 77 (30.8) NA NA 
Breast Cancer Surgery 
   Modified Radical Mastectomy 













Appendix Table 7 Observed and model-estimated subgroups of trajectories for pain and musculoskeletal 
symptoms 
 Baseline 6 months 12 months 18 months 
BPI worst pain     
 Group, mean (SD) 2.51 (3.09) 3.05 (3.43) 2.87 (3.30) 3.05 (3.37) 
 Constant no (observed) 0.37 0.02 0 0 
 Initial no with linear increase (observed) 0.01 0.24 2.08 5.01 
 Constant mild (observed) 2.15 2.76 2.37 1.97 
 Constant moderate (observed) 5.08 6.25 5.89 6.08 
 Constant no (estimated), mean (95% CI) 0.24 (0, 1.04) 0.01 (0, 0.61) 0 (0, 0.05) 0 (0, 0) 
 Initial no with linear increase (estimated) 0.01 (0, 0.54) 0.19 (0, 1.77) 1.58 (0.19, 2.97) 5.02 (1.25, 8.79) 
 Constant mild (estimated) 2.10 (1.26, 2.94) 2.10 (1.26, 2.94) 2.10 (1.26, 2.94) 2.10 (1.26, 2.94) 
 Constant moderate (estimated) 5.60 (4.54, 6.65) 5.60 (4.54, 6.65) 5.60 (4.54, 6.65) 5.60 (4.54, 6.65) 
BPI severity     
 Group, mean (SD) 1.56 (2.06) 1.92 (2.35) 1.86 (2.25) 1.92 (2.31) 
 Constant no (observed) 0.15  0.12  0.07  0.18  
 Constant mild (observed) 1.50  1.88  1.94  1.74  
 Moderate with linear increase (observed) 4.02  4.94  4.77  5.20  
 Constant no (estimated), mean (95% CI) 0.08 (0, 0.48) 0.08 (0, 0.48) 0.08 (0, 0.48) 0.08 (0, 0.48) 
 Constant mild (estimated) 1.66 (1.03, 2.28) 1.66 (1.03, 2.28) 1.66 (1.03, 2.28) 1.66 (1.03, 2.28) 
 Moderate with linear increase (estimated) 4.18 (3.22, 5.14) 4.54 (3.78, 5.29) 4.90 (4.15, 5.65) 5.27 (4.32, 6.21) 
BPI interference     
 Group, mean (SD) 1.22 (2.06) 1.38 (2.08) 1.36 (2.06) 1.40 (2.15) 
 Constant no (observed) 0.14 0.14 0.12 0.18 
 Constant mild (observed) 1.36 1.75 1.84 1.63 
 Constant moderate (observed) 5.11 5.12 4.95 5.26 
 Constant no (estimated), mean (95% CI) 0.14 (0, 0.34) 0.14 (0, 0.34) 0.14 (0, 0.34) 0.14 (0, 0.34) 
 Constant mild (estimated) 1.65 (1.16, 2.14) 1.65 (1.16, 2.14) 1.65 (1.16, 2.14) 1.65 (1.16, 2.14) 
 Constant moderate (estimated) 5.09 (4.34, 5.83) 5.09 (4.34, 5.83) 5.09 (4.34, 5.83) 5.09 (4.34, 5.83) 
BPI usage of analgesics     
 Group, yes (%) 117 (30.8) 121 (32.4) 108 (37.2) 93 (37.7) 
 Constant no (observed) 0.10 0.08 0.09 0.14 
 Linear Increase (observed) 0.64 0.72 0.83 0.79 
 Constant no (estimated), mean (95% CI) 0.10 (0.06, 0.13) 0.10 (0.06, 0.13) 0.10 (0.06, 0.13) 0.10 (0.06, 0.13) 
 Linear Increase (estimated) 0.66 (0.57, 0.74) 0.72 (0.66, 0.79) 0.78 (0.71, 0.85) 0.83 (0.75, 0.91) 
BCPT musculoskeletal subscale (mean)     
Group, mean (SD) 0.83 (0.73) 0.97 (0.78) 0.97 (0.77) 0.99 (0.75) 
Constant no (observed) 0.39 0.43 0.45 0.48 
Mild linear increase (observed) 1.03 1.24 1.25 1.27 
Constant moderate (observed) 2.18 2.42 2.52 2.40 
Constant no (estimated), mean (95% CI) 0.44 (0.35, 0.52) 0.44 (0.35, 0.52) 0.44 (0.35, 0.52) 0.44 (0.35, 0.52) 
Mild linear increase (estimated) 1.08 (0.96, 1.20) 1.16 (1.06, 1.26) 1.24 (1.14, 1.35) 1.32 (1.19, 1.45) 
Constant moderate (estimated) 2.37 (2.26, 2.47) 2.37 (2.26, 2.47) 2.37 (2.26, 2.47) 2.37 (2.26, 2.47) 
BCPT joint pain     
 Group, mean (SD) 1.14 (1.05) 1.43 (1.16) 1.45 (1.19) 1.45 (1.14) 
 Constant no (observed) 0.21 0.16 0.18 0.30 
 Mild quadratic (observed) 1.00 1.36 1.35 1.37 
 Moderate linear increase (observed) 2.56 2.97 3.21 3.12 
 Constant no (estimated), mean (95% CI) 0.14 (0.08, 0.20) 0.14 (0.08, 0.20) 0.14 (0.08, 0.20) 0.14 (0.08, 0.20) 
 Mild quadratic (estimated) 0.98 (0.78, 1.18) 1.29 (1.08, 1.51) 1.42 (1.20, 1.64) 1.34(1.08, 1.59) 
 Moderate linear increase (estimated) 2.70 (2.36, 3.04) 2.92 (2.68, 3.17) 3.13 (2.88, 3.39) 3.32 (3.02, 3.62) 
BCPT muscle stiffness     
 Group, mean (SD) 0.94 (0.98) 1.10 (1.07) 1.10 (1.05) 1.16 (1.03) 
 Constant no (observed) 0.12 0.09 0.13 0.17 
 Mild linear increase (observed) 0.89 1.05 1.08 1.16 
 Moderate linear increase (observed) 2.35 2.73 2.88 2.87 
 Constant no (estimated), mean (95% CI) 0.08 (0, 0.19) 0.08 (0, 0.19) 0.08 (0, 0.19) 0.08 (0, 0.19) 
 Mild linear increase (estimated) 0.88 (0.70, 1.06) 0.97 (0.82, 1.12) 1.07 (0.90, 1.24) 1.17 (0.94, 1.40) 
 Moderate linear increase (estimated) 2.46 (2.06, 2.86) 2.65 (2.34, 2.94) 2.82 (2.51, 3.14) 2.99 (2.57, 3.42) 
Abbreviations: BPI, Brief Pain Inventory; BCPT, Breast Cancer Prevention Trial Symptom Checklist. 
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Appendix Table 8 Significant phenotypic predictors to subgroup membership of pain and musculoskeletal 
symptoms (n=380) 
Predictors B SE OR 95% CI for OR p 
BPI Worst Pain: initial no with linear increase vs constant no 
AI therapy 1.433 0.508 4.189 (1.547, 11.347) 0.005 
Numbers of pregnancies  -0.337 0.162 0.714 (0.519, 0.980) 0.037 
BPI Worst Pain: constant mild vs constant no      
AI therapy 1.205 0.289 3.338 (1.893, 5.887) <0.001 
History of arthritis 1.204 0.355 3.335 (1.664, 6.684) 0.001 
BDI II total (sum) 0.100 0.033 1.105 (1.037, 1.178) 0.002 
BPI Worst Pain: constant moderate vs constant no      
AI therapy 1.576 0.348 4.833 (2.445, 9.554) <0.001 
History of tubal ligation -0.783 0.363 0.457 (0.224, 0.930) 0.031 
History of arthritis 2.418 0.369 11.227 (5.443, 23.155) <0.001 
BDI II total (sum) 0.195 0.035 1.215  (1.135, 1.301) <0.001 
BPI Pain Severity: constant mild vs constant no      
Chemotherapy -0.781 0.377 0.458 (0.219, 0.960) 0.039 
AI therapy 1.365 0.300 3.914 (2.172, 7.052) <0.001 
History of arthritis  1.089 0.330 2.971 (1.557, 5.668) 0.001 
BDI II total (sum) 0.105 0.039 1.111 (1.030, 1.199) 0.007 
BPI Pain Severity: moderate linear increase vs constant no 
Currently married/partnered -0.813 0.398 0.444 (0.203, 0.968) 0.041 
Occupation (level 1 vs 3) -1.218 0.439 0.296 (0.125, 0.700) 0.006 
AI therapy 1.680 0.481 5.366 (2.089, 13.785) <0.001 
History of hysterectomy 1.130 0.430 3.095 (1.334, 7.184) 0.009 
History of arthritis  2.359 0.412 10.584 (4.716, 23.753) <0.001 
BDI II Total (sum) 0.143 0.046 1.154 (1.055, 1.262) 0.002 
POMS Fatigue-Inertia (sum) 0.130 0.039 1.139 (1.055, 1.229) 0.001 
BPI Pain Interference: constant mild vs constant no 
Occupation (level 1 vs 3) -1.299 0.403 0.273 (0.124, 0.601) 0.001 
AI therapy 0.801 0.319 2.227 (1.192, 4.160) 0.012 
History of hysterectomy 0.702 0.344 2.017 (1.028, 3.958) 0.041 
History of arthritis  0.846 0.330 2.331 (1.221, 4.449) 0.010 
Age -0.056 0.028 0.945 (0.896, 0.998) 0.043 
POMS Fatigue-Inertia (sum) 0.074 0.035 1.077 (1.006, 1.153) 0.032 
BPI severity at baseline 0.844 0.119 2.326 (1.843, 2.935) <0.001 
BPI Pain Interference: constant moderate vs constant no 
Occupation (level 1 vs 3) -2.117 0.668 0.120 (0.032, 0.446) 0.002 
AI therapy 1.540 0.653 4.663 (1.296, 16.778) 0.018 
History of hysterectomy 1.472 0.571 4.356 (1.421, 13.351) 0.010 
History of arthritis  1.926 0.573 6.859 (2.231, 21.086) 0.001 
Age -0.143 0.052 0.867 (0.784, 0.959) 0.006 
BDI II Total (sum) 0.187 0.053 1.205 (1.087, 1.337) <0.001 
POMS Tension-Anxiety (sum) 0.106 0.054 1.112 (1.000, 1.237) 0.051 
BPI severity at baseline 1.368 0.161 3.926 (2.861, 5.388) <0.001 
BPI Usage of analgesics: linear increase vs constant no 
Currently married/partnered -0.696 0.292 0.498 (0.281, 0.884) 0.017 
Occupation (level 1 vs 3) -1.011 0.327 0.364 (0.192, 0.691) 0.002 
AI therapy 1.544 0.340 4.682 (2.407, 9.108) <0.001 
First menstrual period age -0.284 0.102 0.753 (0.616, 0.920) 0.006 
POMS Tension-Anxiety (sum) 0.084 0.028 1.087 (1.030, 1.148) 0.002 
BPI severity at baseline 0.665 0.083 1.944  (1.652, 2.288) <0.001 
BCPT Musculoskeletal Symptoms: mild linear increase vs constant no 
AI therapy 0.661 0.275 1.937 (1.129, 3.323) 0.016 
History of arthritis  1.173 0.274 3.233 (1.888, 5.535) <0.001 
BDI II Total (sum) 0.073 0.034 1.076 (1.007, 1.150) 0.031 
POMS Fatigue-Inertia (sum) 0.110 0.031 1.117  (1.051, 1.186) <0.001 
BCPT Musculoskeletal Symptoms: constant moderate vs constant no 
Occupation (level 1 vs 3) -1.383 0.516 0.251 (0.091, 0.690) 0.007 
History of hysterectomy 1.063 0.516 2.894 (1.053, 7.955) 0.039 
History of arthritis 2.312 0.474 10.095 (3.990, 25.539) <0.001 
BDI II Total (sum) 0.149 0.045 1.161 (1.063, 1.267) 0.001 
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Predictors B SE OR 95% CI for OR p 
POMS Fatigue-Inertia (sum) 0.229 0.042 1.257 (1.157, 1.366) <0.001 
BCPT Joint Pain: mild quadratic vs constant no 
Occupation (level 1 vs 3) -1.403 0.447 0.246 (0.102, 0.590) 0.002 
Regularity of period for most of life -1.012 0.492 0.363 (0.139, 0.953) 0.040 
History of arthritis 1.150 0.404 3.159 (1.431, 6.970) 0.004 
POMS Fatigue-Inertia (sum) 0.198 0.046 1.219 (1.114, 1.335) <0.001 
BCPT Joint Pain: moderate linear vs constant no 
Occupation (level 1 vs 3) -1.942 0.544 0.143 (0.049, 0.416) <0.001 
History of menopausal symptoms 1.530 0.557 4.618 (1.549, 13.770) 0.006 
Regularity of period for most of life -1.789 0.615 0.167 (0.050, 0.559) 0.004 
History of arthritis 2.614 0.488 13.660 (5.253, 35.522) <0.001 
POMS Fatigue-Inertia (sum) 0.334 0.051 1.397 (1.264, 1.543) <0.001 
BCPT Muscle Stiffness: mild linear increase vs constant no 
AI therapy 0.673 0.276 1.960 (1.141, 3.368) 0.015 
History of hysterectomy 0.971 0.380 2.640 (1.253, 5.564) 0.011 
POMS Fatigue-Inertia (sum) 0.110 0.041 1.116 (1.029, 1.210) 0.008 
BCPT Muscle Stiffness: moderate linear increase vs constant no 
History of hysterectomy 1.060 0.556 2.887 (0.972, 8.578) 0.056 
History of arthritis 1.683 0.476 5.382 (2.118, 13.675) <0.001 
BDI II Total (sum) 0.135 0.051 1.145 (1.035, 1.265) 0.008 
POMS Fatigue-Inertia (sum) 0.257 0.050 1.293 (1.173, 1.424) <0.001 
Abbreviations: BPI, Brief Pain Inventory; BCPT, Breast Cancer Prevention Trial Symptom Checklist; BDI, Beck 














Appendix Table 9 Summary of significant predictors to subgroup membership across pain and musculoskeletal symptoms 














 INCR MID MOD MID MOD MID MOD Use MID MOD MID MOD MID MOD 
Age      ↓ ↓        
Chemotherapy    ↓           
First menstrual period age        ↓       
Married/Partnered     ↓   ↓       
Occupation (admi vs unskilled)     ↓ ↓ ↓ ↓ ↓ ↓    ↓ 
Regularity of period for most of life         ↓ ↓     
Numbers of pregnancies ↓              
History of tubal ligation   ↓            
AI therapy ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑   ↑  ↑  
Anxiety       B (↑) ↑       
BPI severity at baseline      ↑ ↑ ↑       
Depressive symptoms  ↑ ↑ ↑ ↑  ↑     ↑ ↑ ↑ 
Fatigue     ↑ ↑   ↑ ↑ ↑ ↑ ↑ ↑ 
History of arthritis  ↑ ↑ ↑ ↑ ↑ ↑  ↑ ↑  ↑ ↑ ↑ 
History of hysterectomy     ↑ ↑ ↑    ↑ B (↑)  ↑ 
History of menopausal symptoms          ↑     
 
B: borderline significant; INCR: increase; MID: mild; MOD: moderate; MSK: musculoskeletal. 
↑: increased risk for mild or moderate trajectory; ↓: decreased risk for mild or moderate trajectory 
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Appendix Table 10 Multinomial logistic regression analyses for candidate genes and subgroup membership of 
pain and musculoskeletal symptoms (n=243) 
Predictor B Standard Error p value Odds Ratio 95% CI 
BPI Worst Pain: initial no with linear increase vs constant no 
ESR2 rs2772163 (Dom) -2.385 0.821 0.004 0.092 0.018, 0.460 
AI therapy 1.887 0.715 0.008 6.599 1.625, 26.791 
Numbers of pregnancies -0.733 0.283 0.010 0.480 0.276, 0.837 
LIF rs737812 (Dom) 1.330 0.694 0.055 3.782 0.971, 14.724 
AI therapy 1.542 0.673 0.022 4.673 1.249, 17.483 
Numbers of pregnancies -0.572 0.240 0.017 0.565 0.352, 0.904 
TCL1A rs7158782 (Add) 3.174 1.550 0.041 23.904 1.146, 498.589 
AI therapy 1.580 0.671 0.019 4.856 1.304, 18.086 
Numbers of pregnancies -0.566 0.241 0.019 0.568 0.354, 0.911 
TCL1A rs7159713 (Add) 3.222 1.545 0.037 25.069 1.212, 518.296 
AI therapy 1.495 0.676 0.027 4.459 1.184, 16.786 
Numbers of pregnancies -0.589 0.249 0.018 0.555 0.341, 0.905 
BPI Worst Pain: constant mild vs constant no 
VDR rs731236 (Dom) -0.812 0.398 0.041 0.444 0.203, 0.969 
AI therapy 1.486 0.386 <0.001 4.419 2.073, 9.418 
History of arthritis  1.678 0.544 0.002 5.355 1.842, 15.567 
BDI II total (sum) 0.075 0.046 0.108 1.078 0.984, 1.180 
BPI Worst Pain: constant moderate vs constant no 
CXCL8 rs4073 (Rec) -1.588 0.673 0.018 0.204 0.055, 0.764 
AI therapy 2.460 0.598 <0.001 11.709 3.626, 37.807 
History of arthritis  3.705 0.737 <0.001 40.656 9.595, 172.257 
History of tubal ligation -1.156 0.583 0.047 0.315 0.100, 0.986 
BDI II total (sum) 0.304 0.075 <0.001 1.356 1.171, 1.570 
CYP19A1 rs1008805 (Rec) 1.463 0.588 0.013 4.318 1.364, 13.668 
AI therapy 2.013 0.533 <0.001 7.487 2.635, 21.275 
History of arthritis  3.383 0.664 <0.001 29.461 8.023, 108.174 
History of tubal ligation -1.152 0.576 0.046 0.316 0.102, 0.978 
BDI II total (sum) 0.266 0.067 <0.001 1.304 1.143, 1.488 
VDR rs4516035 (Add) -1.524 0.597 0.011 0.218 0.068, 0.702 
AI therapy 1.935 0.532 <0.001 6.926 2.440, 19.659 
History of arthritis  3.322 0.661 <0.001 27.704 7.588, 101.149 
History of tubal ligation -1.522 0.596 0.011 0.218 0.068, 0.702 
BDI II total (sum) 0.231 0.063 <0.001 1.260 1.114, 1.425 
BPI Pain Severity: constant mild vs constant no 
RANKL rs1054016 (Dom) -0.827 0.357 0.021 0.438 0.217, 0.881 
Chemotherapy -0.979 0.499 0.050 0.376 0.141, 0.999 
AI therapy 1.330 0.377 <0.001 3.780 1.806, 7.910 
History of arthritis  1.267 0.446 0.005 3.550 1.481, 8.509 
BDI II total (sum) 0.149 0.048 0.002 1.161 1.057, 1.276 
BPI Pain Severity: moderate linear increase vs constant no 
CYP19A1 rs1008805 (Rec) 2.422 0.862 0.005 11.271 2.080, 61.081 
Occupation (level 1 vs 3) -1.649 0.708 0.020 0.192 0.048, 0.770 
AI therapy 1.386 0.731 0.058 3.999 0.954, 16.764 
History of hysterectomy 2.582 0.882 0.003 13.223 2.345, 74.552 
History of arthritis  4.135 0.899 <0.001 62.487 10.736, 363.679 
BDI II Total (sum) 0.249 0.099 0.012 1.283 1.056, 1.559 
POMS Fatigue-Inertia (sum) 0.202 0.084 0.016 1.224 1.038, 1.443 
NOS3 rs1799983 (Rec) 1.137 0.578 0.049 3.116 1.003, 9.682 
AI therapy 1.654 0.640 0.010 5.226 1.491, 18.319 
History of hysterectomy 1.943 0.763 0.011 6.978 1.564, 31.135 
History of arthritis  3.264 0.671 <0.001 26.150 7.021, 97.387 
BDI II Total (sum) 0.227 0.083 0.006 1.255 1.067, 1.476 
POMS Fatigue-Inertia (sum) 0.126 0.062 0.040 1.135 1.006, 1.280 
COMT rs887200 (Rec) -1.868 0.808 0.021 0.154 0.032, 0.753 
Occupation (level 1 vs 3) -1.667 0.684 0.015 0.189 0.049, 0.721 
AI therapy 1.112 0.680 0.102 3.041 0.802, 11.531 
History of hysterectomy 2.038 0.820 0.013 7.677 1.539, 38.302 
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Predictor B Standard Error p value Odds Ratio 95% CI 
History of arthritis  3.828 0.799 <0.001 45.968 9.604, 220.016 
BDI II Total (sum) 0.236 0.101 0.019 1.266 1.039, 1.544 
POMS Fatigue-Inertia (sum) 0.162 0.075 0.030 1.176 1.016, 1.361 
COMT rs4633 (Rec) -2.046 0.865 0.018 0.129 0.024, 0.705 
Occupation (level 1 vs 3) -1.731 0.692 0.012 0.177 0.046, 0.687 
History of hysterectomy 2.724 0.849 0.001 15.245 2.886, 80.522 
History of arthritis  3.803 0.813 <0.001 44.821 9.107, 220.595 
BDI II Total (sum) 0.225 0.099 0.023 1.252 1.031, 1.520 
POMS Fatigue-Inertia (sum) 0.193 0.079 0.015 1.212 1.038, 1.416 
BPI Pain Interference: constant mild vs constant no 
VDR rs4516035 (Dom) -0.853 0.398 0.032 0.426 0.195, 0.929 
Occupation (level 1 vs 3) -1.265 0.473 0.008 0.282 0.112, 0.714 
AI therapy 0.948 0.401 0.018 2.580 1.176, 5.662 
History of hysterectomy 0.850 0.461 0.065 2.340 0.948, 5.776 
Age -0.089 0.035 0.011 0.915 0.854, 0.980 
BPI severity at baseline 1.117 0.187 <0.001 3.056 2.118, 4.408 
BCPT Joint Pain: mild quadratic vs constant no 
BDNF rs6265 (Dom) -0.821 0.395 0.038 0.440 0.203, 0.955 
Occupation (level 1 vs 3) -1.230 0.512 0.016 0.292 0.107, 0.797 
Regularity of period for most of life -1.279 0.627 0.041 0.278 0.081, 0.951 
History of arthritis 1.170 0.540 0.030 3.220 1.117, 9.289 
POMS Fatigue-Inertia (sum) 0.215 0.058 <0.001 1.240 1.106, 1.390 
BCPT Muscle Stiffness: mild linear increase vs constant no 
IL1A rs3783521 (Dom) 0.693 0.367 0.059 2.000 0.974, 4.107 
History of hysterectomy 1.733 0.647 0.007 5.658 1.593, 20.096 
POMS Fatigue-Inertia (sum) 0.181 0.056 0.001 1.198 1.074, 1.337 
IL1B rs16944 (Rec) -0.804 0.360 0.026 0.448 0.221, 0.907 
History of hysterectomy 1.403 0.576 0.015 4.069 1.317, 12.574 
POMS Fatigue-Inertia (sum) 0.192 0.057 0.001 1.211 1.083, 1.355 
OPRM1 rs1799971 (Dom) 1.400 0.571 0.014 4.056 1.324, 12.426 
History of hysterectomy 1.434 0.571 0.012 4.193 1.369, 12.842 
POMS Fatigue-Inertia (sum) 0.180 0.056 0.001 1.197 1.072, 1.337 
POMS Fatigue-Inertia (sum) 0.180 0.056 0.001 1.197 1.072, 1.337 
BCPT Musculoskeletal Symptoms: mild linear increase vs constant no 
CYP3A4 rs35599367 (Add) 1.609 0.757 0.034 4.997 1.133, 22.034 
AI therapy 0.888 0.353 0.012 2.431 1.217, 4.856 
History of arthritis  0.906 0.355 0.011 2.474 1.234, 4.959 
BDI II Total (sum) 0.091 0.043 0.036 1.095 1.006, 1.192 
POMS Fatigue-Inertia (sum) 0.110 0.039 0.005 1.116 1.034, 1.205 
IL1RN rs380092 (Rec) -0.618 0.319 0.053 0.539 0.289, 1.008 
AI therapy 0.756 0.342 0.027 2.131 1.090, 4.165 
History of arthritis  0.959 0.354 0.007 2.609 1.303, 5.225 
BDI II Total (sum) 0.098 0.045 0.029 1.103 1.010, 1.205 
POMS Fatigue-Inertia (sum) 0.102 0.039 0.008 1.108 1.027, 1.195 
VDR rs731236 (Rec) -1.332 0.506 0.009 0.264 0.098, 0.712 
AI therapy 0.905 0.346 0.009 2.472 1.254, 4.873 
History of arthritis  1.026 0.358 0.004 2.789 1.383, 5.623 
BDI II Total (sum) 0.104 0.045 0.020 1.110 1.017, 1.212 
POMS Fatigue-Inertia (sum) 0.115 0.040 0.004 1.122 1.037, 1.214 
BCPT Musculoskeletal Symptoms: constant moderate vs constant no 
CYP19A1 rs1008805 (Rec) 1.814 0.787 0.021 6.133 1.313, 28.656 
History of arthritis 2.630 0.775 0.001 13.874 3.037, 63.388 
BDI II Total (sum) 0.170 0.080 0.033 1.185 1.014, 1.385 
POMS Fatigue-Inertia (sum) 0.225 0.069 0.001 1.252 1.093, 1.433 
NOS3 rs1799983 (Rec) 1.636 0.739 0.027 5.135 1.206, 21.868 
History of hysterectomy 1.533 0.859 0.074 4.634 0.861, 24.940 
History of arthritis 2.500 0.723 0.001 12.180 2.952, 50.255 
BDI II Total (sum) 0.135 0.075 0.072 0.144 0.988, 1.325 
POMS Fatigue-Inertia (sum) 0.262 0.067 <0.001 1.299 1.140, 1.482 
OPG rs2073618 (Rec) 1.504 0.733 0.040 4.497 1.069, 18.921 
History of arthritis 2.635 0.737 <0.001 13.946 3.289, 59.136 
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Predictor B Standard Error p value Odds Ratio 95% CI 
BDI II Total (sum) 0.186 0.080 0.020 1.204 1.030, 1.408 
POMS Fatigue-Inertia (sum) 0.190 0.062 0.002 1.210 1.070, 1.367 
NOS3 rs1799983 (Rec) 0.134 0.895 0.881 1.143 0.198, 6.607 
OPG rs2073618 (Rec) -0.368 1.163 0.752 0.692 0.071, 6.769 
NOS3 rs1799983*OPG rs2073618 3.779 1.681 0.025 43.773 1.623, 1180.890 
History of arthritis 2.810 0.819 0.001 16.615 3.337, 82.721 
BDI II Total (sum) 0.175 0.081 0.031 1.191 1.107, 1.396 
POMS Fatigue-Inertia (sum) 0.244 0.072 0.001 1.276 1.107, 1.470 
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Appendix Table 11 Summary of SNPs across phenotypes 
 BPI Worst Pain BPI Severity BPI Interference Analgesics 
Usage 
BCPT Joint Pain BCPT Muscle 
Stiffness 
BCPT MSK 
 INCR MID MOD MID MOD MID MOD Use MID MOD MID MOD MID MOD 
BDNF rs6265         ↓      
CCL2 rs4586   R            
COMT rs4633     ↓          
COMT rs887200     ↓   R       
COMT rs165774 ↑              
CYP17A1 rs4919683              R  
CYP19A1 rs1008805    ↑  ↑ R  R  B    ↑ 
CYP27B1 rs10877012          R     
CYP27B1 rs4646536   R       B     
CYP3A4 rs35599367             ↑  
CXCL8 rs4073 R  ↓            
ESR1 rs9322336  R R            
ESR2 rs2772163 ↓            R  
IGF1 rs6214           R    
IL-6 rs1800795   R   R         
IL1A rs3783521           B    
IL1B rs16944           ↓    
IL1RN rs380092              B  
LIF rs929271 R              
LIF rs737812 R              
MMP13 rs597315   R            
NOS3 rs1799983     ↑         ↑ 
OPG rs2073617             R  R 
OPG rs2073618       R     R  ↑ 
OPRM1 rs1799971            ↑    
RANKL rs1054016     ↓           
TCL1A rs11849538 R      R        
TCL1A rs7158782 ↑              
TCL1A rs7159713 ↑              
TCL1A rs2369049 R              
VDR rs4516035 R R ↓   ↓   R    R  
VDR rs731236  R ↓           ↓  
WNT5A rs1829556             R  
R: significant in univariate analysis, but removed from final model; B: borderline significance; INCR: increase; MID: mild; MOD: moderate; MSK: musculoskeletal. 
↑: increased risk for mild or moderate trajectory; ↓: decreased risk for mild or moderate trajectory
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Figure 3. Patterns of Trajectories for Pain and Musculoskeletal Symptoms (n=380) 
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Appendix C PRELIMINARY WORK #1: SYMPTOM MAP OF ENDOCRINE THERAPY 















Appendix D PRELIMINARY WORK #2: GENETIC UNDERPINNINGS OF 
MUSCULOSKELETAL PAIN DURING TREATMENT WITH AROMATASE 
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